

Daniel E. Spratt, M.D.
Chair, Radiation Oncology
Vincent Smith Professor
University Hospitals Seidman Cancer Center
Case Western Reserve University
11100 Euclid Ave
Cleveland, OH 44106
Phone: (216) 844-3951
Email: daniel.spratt@uhhospitals.org

Education and Training

Education

01/2003-05/2006 BS, Georgia State University, Atlanta, GA.
08/2006-05/2010 MD, Medicine MD Degree, Vanderbilt, Nashville, TN

PostDoctoral Training

07/2010-06/2011 Internship, Transition year, Spartanburg Regional Healthcare System, Spartanburg, SC
07/2011-06/2015 Residency, Radiation Oncology, Memorial Sloan Kettering, New York, NY

Certification And Licensure

Certification

05/2017-present American Board of Radiology - Radiation Oncology #68073

Licensure

06/2011-09/2016 State of New York, Medical License
03/2015-05/2021 State of Michigan, Controlled Substance
03/2015-05/2021 State of Michigan, Medical License
03/2015-present State of Ohio, DEA Registration
05/2021-present State of Ohio, Medical License

Academic, Administrative, Clinical, Research and Military Appointments

Academic Appointments

08/2015-08/2018 Clinical Assistant Professor in Radiation Oncology, University of Michigan, Ann Arbor, MI
09/2018-10/2020 Clinical Associate Professor in Radiation Oncology, University of Michigan, Ann Arbor, MI
10/2020-04/2021 Professor with Tenure, University of Michigan, Ann Arbor, MI (Tenured)
04/2021-present Adjunct Professor, University of Michigan - Ann Arbor, Ann Arbor, Michigan
05/2021-present Professor with Tenure, Case Western Reserve University School of Medicine/University Hospitals, Cleveland, Ohio (Tenured)

Administrative Appointments

08/2015-05/2021 Director, Spine Oncology Program, University of Michigan, Ann Arbor, MI
08/2017-05/2021 Co-Chair, Genitourinary Clinical Research Team, University of Michigan, Ann Arbor, MI
12/2017-05/2021 Associate Chair, Clinical Research, University of Michigan, Ann Arbor, MI
01/2018-05/2021 Fellowship Director, University of Michigan, Ann Arbor, MI
05/2021-present Chairman of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH
05/2021-present Chairman of Radiation Oncology, University Hospitals, Seidman Cancer Center, Cleveland, Ohio

Clinical Interests

Prostate cancer

- Prostate cancer
- Spine metastases

Research Interests

- Development and validation of prognostic and predictive biomarkers in prostate cancer.
- Translational clinical trials in prostate cancer.
- Prostate cancer health disparities.

Grants

Current Grants

NIH U-01: Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer NIH-DHHS-US- 20-PRE00121

Spratt, Daniel, PI

08/2021-11/2026. \$2,454,000 (\$496,000)

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS) Janssen- 20-PAF03677 Daniel Spratt, PI

05/2020-05/2025. \$2,100,000 (\$400,000)

5 R01 CA240991-05: Determining the clinical impact of gene expression testing in localized prostate cancer NIHDHHS-US- 19-PAF00899

Daniel Spratt (multi-PI Todd Morgan). Co-PI

07/2019-06/2024. \$3,747,856 (\$498,000)

Submitted Grants

Development of a novel staging system for metastatic cancer using STARS phenotypes SubK-NIH-DHHS-US through a consortium with Pennsylvania State University- 21-PAF05523

Co-I

01/2022-12/2026. \$520,224

Comprehensive assessment of a novel clinical trial platform in urology Urology Care Foundation- 21-PAF02606

Co-I without Effort (Principal Investigator: Singhal, Udit) 07/2021-06/2023. \$80,000

A phase II randomized trial of moderate versus ultra-hypofractionated post-prostatectomy radiation therapy National Comprehensive Cancer- 21-PAF04915

Co-I without Effort (Principal Investigator: Jackson, William) 07/2021-6/2023.
\$300,000

Past Grants

5 P50 CA186786-10: Michigan Prostate SPORE NIH-DHHS-US- 19-PAF00149

Co-I with Effort (Principal Investigator: Arul M Chinnaiyan) 10/2020-05/2021. (\$1,783,426)

Diversity Supplement- Determining the clinical impact of gene expression testing in localized prostate cancer NIHDHHS-US- 20-PAF05933

Daniel Spratt (multi-PI Todd Morgan), Co-PI

06/2020-08/2021. \$78,587

G024719: Impact of Statewide Quality Collaboratives on Prostate Cancer Disparities in Michigan Department of Urology Prostate Cancer Research Grant

Daniel Spratt (co-PI Robert Dess). I am responsible for assessing disparities in surgical care., Co-PI 04/2020-05/2021. \$50,000 (\$50,000)

G024686: Molecular Characterization of Radiation Resistance in Prostate Cancer Department of Urology Prostate Cancer Research Grant

Daniel Spratt (co-PI Salami). My role is acquire and sequence post-RT biopsy proven local failures., Co-PI 04/2020-05/2021. \$50,000 (\$50,000)

2 P50 CA186786-07S1: Michigan Prostate SPORE NIH-DHHS-US- 19-PAF00149; 20-PAF02244

Co-I with Effort (Principal Investigator: Arul M Chinnaiyan) 09/2019-05/2021. \$10,268,218

Large-scale discovery and validation of predictive biomarkers for immunotherapy across cancers and treatments V Fdn for Cancer Research, The- 19-PAF07579

Co-I without Effort (Principal Investigator: Marcin Piotr Cieslik)

08/2019-08/2022. \$600,000 (\$182,000)

NRG Oncology Clinical Trial Fixed Price Subaward SubK-NIH-DHHS-US through a consortium with NRG Oncology- 20-PAF02125

Daniel Spratt, PI

08/2019-05/2021. \$120,000 (\$30,186)

P50CA186786: Quality of life and circulating tumor monitoring for men receiving neoadjuvant SBRT prior to prostatectomy for high risk prostate cancer Prostate SPORE-Subaward

Daniel Spratt, PI

10/2018-10/2020. \$120,000 (\$60,000)

Non-invasive interrogation of oligometastatic castration-resistant prostate cancer and the benefit of metastasis directed therapy in the Phase II FORCE randomized clinical trial Prostate Cancer Foundation- 18-PAF05722

Other (Principal Investigator: Zachery Reichert (Mentor- Daniel Spratt)) 08/2018-08/2021. \$225,000 (\$75,000)

5 P30 CA046592-31S1: *Development of a Standardized Electronic Treatment Plan Builds for NCI-supported Clinical Trials* NIH-DHHS-US- 17-PAF05471; 19-PAF03268; 21-PAF00256

Co-I with Effort (Principal Investigator: Eric R Fearon)

07/2018-05/2021. \$36,749,525

3 P30 CA046592-30S3: *NIH Cancer Clinical Investigator Team Leadership Award (FY) 2019* NIH-DHHS-US- 17PAF05471; 20-PAF01501; 19-PAF03268

Daniel Spratt, PI

07/2018-05/2021. \$125,000 (\$25,000)

5 P30 CA046592-31: *Access to Experimental Therapeutics Clinical Trials Network (ETCTN) Agents at Univ of Michigan Site* NIH-DHHS-US- 17-PAF05471; 19-PAF03268; 20-PAF01501

Co-I with Effort (Principal Investigator: Eric R Fearon)

07/2018-05/2021. \$34,711,738

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide (FORMULA-509 Trial) Janssen Scientific through a consortium with Dana-Farber Cancer Institute- 18-PAF05501

Daniel Spratt, Site-PI

04/2018-05/2021. \$163,798 (\$22,663)

P50CA186786: SPORE in Prostate Cancer NCI

Co-I with Effort (Principal Investigator: Chinnaiyan)

07/2017-08/2019. \$1,610,903

A PHASE I TRIAL OF NEOADJUVANT STEREOTACTIC BODY RADIOTHERAPY PRIOR TO RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER Clinical Translational Resource Allocation Committee (CTRAC)- UMCC 2016.106 (HUM00120414)

Daniel Spratt, PI

12/2016-12/2020. \$150,000 (\$150,000)

ARN-509+Abiraterone acetate+Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study Janssen Scientific through the Prostate Cancer Clinical Trial Consortium- 16-PAF07711

Daniel Spratt, PI

11/2016-05/2021. \$112,237 (\$20,206)

PC151068: Genotoxic Stress and Androgen Receptor Signaling: Integration of Dynamic Non-invasive Biomarkers Post-Radiotherapy in Prostate Cancer Army-DoD-US- 16-PAF00561

Spratt, Daniel, PI

09/2016-09/2020. \$803,811 (\$200,581)

5 UG1 CA233160-06: UM LAPs -UG1 Grant NIH-DHHS-US- 18-PAF03934

Co-I with Effort (Principal Investigator: Mark M Zalupski)

05/2016-5/2021. (\$713,720)

1R21CA191913-01A1: AUGER ELECTRON RADIOTHERAPY OF LATE-STAGE, CASTRATION-RESISTANT PROSTATE CANCER USING A BROMINATED DIHYDROTESTOSTERONE ANALOGUE NIH

Co-I (Principal Investigator: Darren Veach)

12/2015-11/2017. \$191,291 (\$50,000)

Subaward Agreement for Protocol ENZA-13L21: Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA Recurrent Prostate Cancer after Radical Prostatectomy Astellas Pharma US, Inc. through a consortium with Johns Hopkins University- 15-PAF06380

Daniel Spratt, PI

06/2015-01/2020. \$100,320 (\$20,064)

Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy Astellas Pharma US, Inc. through a consortium with Johns Hopkins University- 20-PAF04097

Daniel Spratt, PI

06/2015-05/2021. \$125,000 (\$1,281)

Funding Agreement: True NTH USA Interventions in Prostate Cancer Livestrong Foundation- 15-PAF05268 Co-I with Effort (Principal Investigator: Daniela Amdur Wittmann)

03/2015-02/2018. \$1,164,537 (\$388,179)

Schedule 2-Funding : True NTH Sexual Recovery Intervention in Prostate Cancer Livestrong Foundation- 21PAF01975

Co-I with Effort (Principal Investigator: Daniela Amdur Wittmann) 03/2015-12/2020. (\$95,304)

Schedule 2 Funding: True NTH Sexual Recovery Intervention in Prostate Cancer Livestrong Foundation- 19PAF06307

Co-I with Effort (Principal Investigator: Daniela Amdur Wittmann)

03/2015-02/2020. (\$96,782)

14-PAF06860: A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Renal Cell Carcinoma Varian Medical Systems

Daniel E. Spratt, PI

07/2014-06/2019. \$410,156 (\$136,718)

Phase 1 Trial of [18F] Dihydro-testosterone PET and MR imaging in patients with localized prostate cancer. Sponsor: Imaging and Radiation Sciences (IMRAS) Grant. Imaging and Radiation Sciences (IMRAS)

Daniel E Spratt, PI

07/2014-12/2016. \$125,000 (\$62,500)

5 U10 CA180801-05: UM LAPs -U10 Grant NIH-DHHS-US- 13-PAF03445

Co-I with Effort (Principal Investigator: Mark M Zalupski)

04/2014-02/2019. \$4,019,495 (\$805,799)

Young Investigator Award: Non-invasive molecular imaging to monitor androgen receptor activity in prostate cancer post radiation therapy. Prostate Cancer Foundation

Daniel E Spratt, PI

01/2014-01/2019. \$225,000 (\$75,000)

Non-invasive molecular imaging to monitor androgen receptor activity in prostate cancer post radiation therapy
RSNA Research Resident Grant

Daniel E. Spratt, PI

07/2013-06/2014. \$30,000

Impact of radiotherapy on androgen receptor signaling and methods for non-invasive imaging Imaging and Radiation Sciences (IMRAS) Grant

Daniel E Spratt, PI

07/2012-12/2014. \$100,000

Honors and Awards

International

| | |
|-----------|--|
| 2012 | World Congress of Brachytherapy/ESTRO - Travel Award - International |
| 2013 | European Urology's Award for Best Resident Publication |
| 2016 | International Journal of Radiation, Biology, and Physics Top Reviewer Award for 2016 |
| 2017-2018 | Star Reviewer Award for Urologic Oncology: Seminars and Original Investigations |
| 2018 | Steve Liebel Award |
| 2019 | European Urology Reviewer of the Month Award |
| 2019 | European Urology Reviewer of the Year Award |
| 2019 | Next Generation Innovator Award (HemeOnc Today) |

National

| | |
|-----------|---|
| 2014-2015 | RSNA Resident Research Roentgen Award for Outstanding Research |
| 2014 | ASTRO's 56th Annual Basic Science Abstract Award in the Biology |
| 2019-2021 | Cancer Clinical Investigator Team Leadership Award (CCITLA) NIH Award |

Regional

| | |
|------|---|
| 2006 | 1st place at the 14th Suddath Symposium of Molecule Dynamics in Biology Competition |
|------|---|

Institutional

| | |
|------|--|
| 2005 | University Research Scholar, Georgia State University |
| 2006 | Overall Best Undergraduate Award; Georgia State University |
| 2006 | Summa Cum Laude - Institutional |
| 2007 | Amos Christie Summer Scholar Recipient |
| 2009 | StarBRITE (The Biomedical Research, Integration, Translation and Education portal) Microgrant recipient, Vanderbilt University Medical Center |
| 2009 | Winner of Vanderbilt Ingram Cancer Center poster competition |
| 2010 | AQA (Alpha Omega Alpha) Honor Society Recipient |
| 2014 | Chief Resident, Memorial Sloan Kettering Cancer Center |
| 2016 | Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award |
| 2016 | Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award |
| 2017 | Annual Clinical Faculty Teacher of the Year Award |
| 2018 | Dean's Award for Clinical Research |
| 2019 | GME Teacher/Mentor of the Year Award |

2020 Outstanding Clinical Research Award, Rogel Cancer Center

Memberships in Professional Societies

2010-present Member, Alpha-Omega-Alpha Honors Society
2010-present Member, American Board of Radiology
2010-present Member, Radiological Society of North America
2011-present Member, American Brachytherapy Society
2012-present Member, American Society of Clinical Oncology
2012-present Member, American Society of Therapeutic Radiation Oncology
2012-present Member, Prostate Cancer Foundation
2016-present Member, NRG

Editorial Positions, Boards, and Peer-Review Service Study Sections

International

2015-present Prostate Grants UK- Grant Reviewer (Ad Hoc)
2016-present Prostate Cancer Foundation Grant Reviewer for Challenge Awards (\$1 million awards)
2017 Prostate Cancer Canada Study Section (awards two \$1.5 million grants) (Ad Hoc)
2018 The Fonds de Recherche du Québec –Santé (FRQS). Oncopole EMC2 (Multi-institutional teams against cancer). The total budget of this program is CAD \$6M and the program will give a maximum of CAD \$1.5M/project over 3 years. (Ad Hoc)

National

2015-present Prostate Cancer Foundation Grant Reviewer for the Radiotherapy and Radiobiology Section for Young Investigator Awards (Ad Hoc)
2016-2017 Department of Defense: Prostate Cancer Health Disparities Study Section (Ad Hoc)
2016-present American Society for Radiation Oncology (ASTRO) Genitourinary Abstract Reviewer
2019 Department of Defense: Prostate Cancer Health Disparities Study Section (Ad Hoc)
2019 NIH Small Business Innovation Research (SBIR) Study Section (Ad Hoc)
2019 UCSF Benioff Initiative for Prostate Cancer Research- 1 Year High Impact Awards for Advanced Prostate Cancer (Ad Hoc)
2020 External Advisory Board to University of Alabama, Cancer Center Program With An Emphasis on the Genitourinary Program and Radiation Oncology (Ad Hoc)

Institutional

2018 Blue Boxer Prostate Cancer Grant Reviews (Ad Hoc)
2018 Prostate Cancer SPORE Career Development Awards (Ad Hoc)
2019 Michigan Health Science Seminar Reviews For Disparity Awards (Ad Hoc)

Editorial Boards

2016-present Associate Editor, Prostate Cancer Foundation Patient Guide
2017-2020 Associate Senior Editor, International Journal of Radiation Oncology Biology and Physics. Genitourinary Division.
2017-present Associate Editor, Nature- Prostate Cancer and Prostatic Diseases
2019-2020 Guest Editor, Guest Editor to The Cancer Journal: The Journal of Principles & Practice of Oncology. The latest advances in prostate cancer, from hormone sensitive to metastatic castration-resistant prostate cancer, were covered across 13 articles.
2020-2023 Senior Editor, International Journal of Radiation Oncology Biology and Physics. Genitourinary Division.

Journal Reviewer

2013-present Annals of Internal Medicine (Ad Hoc)

| | |
|--------------|---|
| 2013-present | Current Cancer Therapy Review (Ad Hoc) |
| 2013-present | European Journal of Cancer Care (Ad Hoc) |
| 2013-present | International Journal of Radiation Oncology * Biology * Physics (Ad Hoc) |
| 2013-present | Practical Radiation Oncology (Ad Hoc) |
| 2014-present | Prostate Cancer (Ad Hoc) |
| 2014-present | Radiotherapy and Oncology (Ad Hoc) |
| 2015-present | British Journal of Cancer (Ad Hoc) |
| 2015-present | European Urology (Ad Hoc) |
| 2015-present | PLOS ONE (Ad Hoc) |
| 2016-present | Austin Journal of Radiation Oncology and Cancer (Ad Hoc) |
| 2016-present | Bladder Cancer (Ad Hoc) |
| 2016-present | Brachytherapy (Ad Hoc) |
| 2016-present | Clinics in Oncology (Ad Hoc) |
| 2016-present | European Journal of Neurology (Ad Hoc) |
| 2016-present | Frontiers Oncology (Ad Hoc) |
| 2016-present | International Journal of Environmental Research and Public Health (Ad Hoc) |
| 2016-present | JAMA Oncology (Ad Hoc) |
| 2016-present | JCO Clinical Cancer Informatics (Ad Hoc) |
| 2016-present | JSM Surgical Oncology and Research (Ad Hoc) |
| 2016-present | Journal of Surgery (Ad Hoc) |
| 2016-present | Prostate Cancer and Prostatic Diseases - Nature (Ad Hoc) |
| 2016-present | The Cancer Journal: The Journal of Principles & Practice of Oncology (Ad Hoc) |
| 2016-present | The Journal of Urology (Ad Hoc) |
| 2016-present | Translational Oncology (Ad Hoc) |
| 2017-present | Advances in Radiation Oncology (Ad Hoc) |
| 2017-present | Asian Journal of Andrology (Ad Hoc) |
| 2017-present | Cancer Research (AACR) (Ad Hoc) |
| 2017-present | Journal of Medical Imaging and Radiation Oncology (Ad Hoc) |
| 2017-present | Journal of Radiology & Radiation Therapy (Ad Hoc) |
| 2017-present | Journal of Radiology and Oncology (Ad Hoc) |
| 2017-present | Journal of Stem Cell Therapy and Transplantation (Ad Hoc) |
| 2017-present | Lancet Oncology (Ad Hoc) |
| 2017-present | Oncotarget (Ad Hoc) |
| 2017-present | Technology in Cancer Research & Treatment (Ad Hoc) |
| 2018-present | Clinical Genitourinary Cancer (Ad Hoc) |
| 2018-present | EClinicalMedicine- The Lancet (Ad Hoc) |
| 2018-present | Experimental and Molecular Pathology (Ad Hoc) |
| 2018-present | Journal of the National Cancer Center Network (JNCCN) (Ad Hoc) |
| 2018-present | World Journal of Urology (Ad Hoc) |
| 2019-present | Cancer Epidemiology, Biomarkers & Prevention (Ad Hoc) |
| 2019-present | Clinical Cancer Research (Ad Hoc) |
| 2019-present | European Urology Focus (Ad Hoc) |
| 2019-present | JAMA Network Open (Ad Hoc) |
| 2019-present | JNCI: Journal of the National Cancer Institute Oxford Academic (Ad Hoc) |
| 2019-present | Urology (Ad Hoc) |
| 2020-present | European Urology Open Science (Ad Hoc) |

| | |
|--------------|--|
| 2020-present | GENE (Ad Hoc) |
| 2020-present | Journal of Clinical Oncology (JCO) (Ad Hoc) |
| 2020-present | Journal of Clinical Oncology Precision Oncology (Ad Hoc) |

Teaching

Advanced Post Graduate Fellow

| | |
|-----------------|---|
| 08/2015-07/2017 | Ahmed Abugharib, MD, University of Michigan. Currently. He is now a Clinical Oncologist & Lecturer of Clinical Oncology at Sohag University, Sohag, Egypt |
| 10/2020-08/2022 | Liat Hammer, MD/PhD, University of Michigan |

Clinical Fellow

| | |
|-----------------|---|
| 01/2019-present | Jeffrey Tosoain, MD, University of Michigan |
| 06/2019-present | Randy Vince, MD, University of Michigan |

Faculty Member

| | |
|-----------------|--|
| 08/2017-present | Samuel Kaffenberger, MD, Department of Urology, University of Michigan |
| 01/2018-present | Zachary Reichert, MD, Department of Medicine, University of Michigan |

Graduate Student

| | |
|-----------------|---|
| 07/2017-07/2019 | Krithika Suresh, PhD, University of Michigan. |
| 07/2019-present | Elizabeth Chase, PhD, University of Michigan |

Medical Student

| | |
|-----------------|--|
| 01/2012-06/2015 | Michael Doran, MD, Memorial Sloan Kettering Cancer Center. |
| 01/2016-07/2017 | Moaz Soliman, BS, University of Michigan Medical School |
| 06/2017-09/2017 | Nolan Pearson, BS, University of Michigan |
| 01/2018-01/2020 | David Wallington, BS, Western Michigan. |
| 01/2018-present | Michael T. Broderick, BS, University of Michigan |
| 02/2019-present | Neil Jaraith, BS, University of Michigan |
| 06/2019-present | Aulina Chowdury, BS, Eastern Michigan |
| 07/2019-present | Sean Miller, MD, University of Michigan. |

Resident/House Officer

| | |
|-----------------|--|
| 07/2013-06/2017 | Jonathan Leeman, MD, Memorial Sloan Kettering Cancer Center. |
| 07/2015-06/2019 | William Jackson, MD, University of Michigan. |
| 08/2015-06/2016 | Jae Lee, MD/PhD, University of Michigan. |
| 09/2015-06/2018 | Robert Dess, MD, University of Michigan. |
| 01/2016-03/2017 | Dan Wahl, MD/PhD, University of Michigan. |
| 01/2016-06/2017 | Payal Soni, MD, University of Michigan. |
| 07/2016-06/2020 | George Zhou, MD, University of Michigan. |
| 11/2016-06/2020 | Whitney Beeler, MD, University of Michigan. |
| 01/2017-06/2019 | Steven Allen, MD/PhD, University of Michigan |
| 07/2018-present | Laila Gharzai, MD, University of Michigan |
| 01/2019-present | Samuel Birer, MD, University of Michigan |
| 06/2019-present | Matthew McFarlane, MD/PhD, University of Michigan |
| 09/2019-present | Elizabeth Jaworksi, MD, University of Michigan |
| 12/2020-present | Krystal Morales Rivera, MD, University of Michigan |

Undergraduate Student

| | |
|-----------------|---|
| 12/2015-present | Robert Simons, BS, University of Michigan |
| 06/2019-present | Munna Hazime, BS, University of Michigan |

06/2019-present Tanya Hammound, BS, University of Michigan

Teaching Activity

Institutional

01/2003-01/2005 Instructor for Organic and General Chemistry. Role: Teacher of Chemistry to Undergraduate students. Georgia State University, Atlanta, GA

01/2003-01/2005 Pre-Medical Tutor. Role: Tutored pre-medical students in basic science courses. Georgia State University, Atlanta, GA

01/2006-01/2010 Tutor in Anatomy and Microbiology. Role: Tutored medical students in multiple courses. Vanderbilt Medical School, Nashville, TN

01/2012-01/2015 Breast Cancer. Role: Lecturer to Radiation Therapy Students. Memorial Sloan Kettering Cancer Center, New York, NY

01/2013-01/2015 Prostate Cancer Review. Lecturer to Radiation Oncology Residents. Memorial Sloan Kettering Cancer Center, New York, NY

01/2013-01/2015 Cutaneous Malignancy Review. Lecturer to Radiation Oncology Residents. Memorial Sloan Kettering Cancer Center, New York, NY

06/2015 Rogel Cancer Center Grand Rounds: The utility of prognostic and predictive biomarkers to achieve precision prostate cancer care

08/2015 PSA Screening A debate among 12 radiation oncology residents regarding the use and data supporting PSA screening in prostate cancer.

09/2015 Active Surveillance. A debate among 12 radiation oncology residents regarding the use of active surveillance in prostate cancer.

09/2015 Low/Intermediate Risk Prostate Brachy/Dose-escalation

10/2015 Whole brain radiotherapy treatment field design Live demonstration of how to design whole brain radiotherapy fields.

10/2015 Resident Research: Dos and Dents. A high-yield lecture to radiation oncology residents about the importance of resident research, and pitfalls to be careful of.

10/2015 Resident and Life Efficiency: Do what you need and want. A lecture to radiation oncology residents on how to improve efficiency in life.

10/2015 Interplay of Radiotherapy and Androgen Deprivation Therapy. Lecture to physicians and physician scientists in radiation oncology regarding the important synergy of combination therapy for prostate cancer.

12/2015 Principles and Practice of Radiation Oncology. Lecture given to the hematology/oncology fellowship program to review the essentials that they need to know about radiation oncology and radiotherapy.

02/2016 Prostate Cancer 101 for the Radiation Therapist. Lecture to the Radiation Therapy Technologist (RTT) students.

02/2016 Improving your Job Hunting Skills. A lecture to radiation oncology residents on how to apply and improve your ability to obtain the job they want.

06/2016 Journal Club Leader for the Department of Radiation Oncology.

06/2016 Genitourinary Mock Oral Examiner. End of year practice oral board session for the radiation oncology residents.

07/2016 Management of spinal metastases and spinal cord compression. Lecture to radiation oncology residents.

08/2016 Prostate Cancer 101 for the Radiation Oncology Resident. A lecture to radiation oncology residents on yield topics of prostate cancer.

08/2016 Hypofractionated Radiotherapy: Are we ready for it? A debate. A lecture to radiation oncology residents on recent evidence for moderately hypofractionated radiotherapy in prostate cancer.

01/2017 Statistics in Radiation Oncology and Application to Prostate Cancer Quality of Life. A lecture to the introductory Masters level statistics course offered at University of Michigan to review a real research question on the topic of quality of life for men with prostate cancer.

01/2017 Management of Favorable Intermediate Risk Prostate Cancer. Lecture to the radiation oncology residents.

01/2017 Radiotherapeutic Management of Spinal Astrocytomas. Lecture to the Department of Neurosurgery residents, fellows, and faculty.

02/2017 Rapid Review Course: Ocular and Cutaneous Cancers. A new curriculum I started to provide high-yield information in a rapid fashion for radiation oncology residents.

02/2017 Rapid Review Course: Pediatric Cancers. A new curriculum I started to provide high-yield information in a rapid fashion for radiation oncology residents.

02/2017 Rapid Review Course: Genitourinary Cancers. A new curriculum I started to provide high-yield information in a rapid fashion for radiation oncology residents.

03/2017 Rapid Review Course: Gastrointestinal Cancers. A new curriculum I started to provide high-yield information in a rapid fashion for radiation oncology residents.

03/2017 Prostate cancer for the Radiation Therapy Technologist (RTT). A lecture to the radiation therapists at the University of Michigan to review anatomy, pathology, staging, and treatment that is relevant to their practice.

03/2017 Rapid Review Course: Thoracic Cancers. A new curriculum I started to provide high-yield information in a rapid fashion for radiation oncology residents.

03/2017 Prostate Cancer Review for the Radiation Therapist. Lecture to the Radiation Therapy students on specifics of simulation and treatment of prostate cancer.

04/2017 Looking Towards the Future: Career and Research Advice. Joint lecture with the radiation oncology faculty the the residents on how to succeed in research and life.

04/2017 Pediatric CNS Malignancies: Germinoma and Ependymoma. Lecture to the University of Michigan Radiation Oncology Residents.

04/2017 Pediatric CNS Malignancies: Medulloblastoma. Lecture to the University of Michigan Radiation Oncology residents.

04/2017 Journal Club Leader for the Department of Radiation Oncology. Reviewed RTOG 9601 and the Genomic Adjusted Radiotherapy Dose papers for the department of radiation oncology.

07/2017 Treatment of spinal cord compression. Lecture to medical students and radiation oncology residents.

07/2017 Overview of spine SBRT and critical review of the ASTRO guidelines. Lecture to medical students and radiation oncology residents.

07/2017 Updates to PSA screening guidelines. Lecture to radiation oncology residents and M4 medical students.

08/2017 Evolution and history of androgen deprivation therapy for localized prostate cancer. Lecture to radiation oncology residents and M4 medical students.

08/2017 Urology Grand Rounds: Evolution and Overview of Prostate Cancer Radiotherapy in 2017

08/2017 Side effects of hormone therapy. Lecture to radiation oncology residents and M4 medical students.

08/2017 Active surveillance for low risk prostate cancer. Lecture to radiation oncology residents and M4 medical students.

12/2017 Spine Treatment Planning Conference

01/2018 Treatment of Localized Prostate Cancer from a Radiation Oncologist Vantage Point. Lecture to the Urology fellowship and residency programs.

02/2018 Statistics in clinical medicine. Lecture to the radiation oncology residency program with a hands on tutorial on how to perform descriptive and survival statistics.

02/2018 Active surveillance for localized prostate cancer. Lecture to the radiation oncology residency program.

02/2018 Post-operative radiotherapy for recurrent prostate cancer. Lecture to the radiation oncology residency program.

10/2018 Treatment of Localized Prostate Cancer: A Radiation Oncologist Viewpoint for the Urologist

01/2019 Radiation Oncology Overview for the Heme Onc Fellows

| | |
|---------|--|
| 04/2019 | Fundamentals of Clinical Trials: Part 2 |
| 04/2019 | Oral Boards Review- 2019 |
| 08/2019 | Intermediate Risk Prostate Cancer- Radiation Oncology Residents and Fellows |
| 08/2019 | Low Risk Prostate Cancer- Radiation Oncology Residents and Fellows |
| 08/2019 | Personalizing Post-Operative Prostate Cancer- Radiation Oncology Residents and Fellows |
| 08/2019 | Post-Operative Prostate Cancer Debate- Radiation Oncology Residents and Fellows |
| 12/2019 | Departmental journal club to review the latest randomized evidence for prostate SBRT. |
| 03/2020 | Biostatistics for Urologic Oncology Fellows |

Dissertation Committees

| | |
|------|---|
| 2019 | Holly Hartman, Integration of the competing risks of Covid-19- and cancer-specific mortality from treatment delay during the global pandemic., University of Michigan, School of Public Health- Department of Biostatistics, Committee Member |
|------|---|

Committee and Administrative Services Committee Services

International

| | |
|--------------|--|
| 2012-2015 | International Spine Radiosurgery Consortium, Member |
| 2014-present | Prostate Cancer Foundation, Chair of Radiation Therapy Working Group |
| 2015-2017 | Prostate Cancer Foundation: Radiobiology Working Group, Co-Chair |
| 2016-2019 | American Society of Clinical Oncology (ASCO), Genitourinary (non-prostate) Scientific Program Committee Member |
| 2016-present | American Society for Radiation Oncology (ASTRO), Annual Scientific Meeting Genitourinary Reviewer |
| 2017-present | International Spine Oncology Consortium (SpOC), Chair |
| 2018-present | Prostate Cancer Foundation: Disparities Working Group, Co-Chair |
| 2020-present | American Society of Clinical Oncology (ASCO) Cancer Research Committee, Member |

National

| | |
|--------------|--|
| 2007-2008 | Health Policy AMSA, Vice President |
| 2014-2015 | ACR Unsealed Source National Guidelines, Committee Member |
| 2016-present | NRG Cooperative Group, Genitourinary Core Committee Member |
| 2019-present | NRG Cooperative Group Genitourinary Committee, Subcommittee Chair for Intact Prostate Cancer |
| 2019 | Society of Urology Oncology, Annual scientific meeting committee member |
| 2020-2023 | NCI NCTN Genitourinary Steering Committee, Special Committee Member |
| 2020-present | American Urological Association (AUA) Clinical Trials Education Steering Committee, Member |

Regional

| | |
|-----------|--|
| 2018-2021 | Michigan Radiation Oncology Quality Consortium (MROQC), Prostate Cancer Lead |
| 2019-2021 | Michigan Society of Hematology and Oncology (MSHO), Member |

Institutional

| | |
|-----------|--|
| 2008 | Vanderbilt Wellness Committee Nutrition and Exercise, Educator |
| 2010-2011 | Accreditation Council for Graduate Medical Education, Council Leader |
| 2011-2015 | Memorial Sloan Kettering Wellness Champion, Resident leader |
| 2014-2015 | Chief Resident-Memorial Sloan Kettering, Chief Resident |
| 2015-2021 | Radiation Oncology Residency Interview Committee, Reviewer/Speaker |
| 2015-2021 | University of Michigan Cancer Center Lead Academic Participating Sites (LAPS) Board of Directors, Member |
| 2015-2021 | University of Michigan's Spine Oncology Program, Director |

| | |
|-----------|--|
| 2016-2021 | University of Michigan Cancer Center- Genitourinary Division, Chair of Clinical Research |
| 2016-2021 | University of Michigan's Department of Radiation Oncology Re-Irradiation Committee, Member |
| 2017-2021 | Michigan Legacy Tissue Program (MLTP), Member |
| 2017-2021 | University of Michigan Comprehensive Cancer Center, Core Grant Member |
| 2019-2020 | GME Awards Selection Committee, Member |
| 2019-2021 | CTSU Advisory Board, Member |

Visiting Professorships and Extramural Invited Presentations

Visiting Professorships

| | |
|-----------------|--|
| 06/2014 | HK2 and androgen receptor signaling in prostate cancer post radiation: non-invasive serum markers to capture dynamic changes with therapy, Mayo Clinic, June 2014, Rochester, MN |
| 08/2016 | Interplay of DNA Repair and AR-signaling: Clinical Translation, Karmanos Cancer Center, Wayne State, Department of Medical Oncology, August 2016, Detroit, MI |
| 03/2017 | Personalizing Treatment through Prognostic and Predictive Biomarkers, UT Southwestern, March 2017, Dallas, TX |
| 08/2017 | Development of Predictive Biomarkers to Guide the Treatment of Prostate Cancer, GenomeDx, August 2017, Vancouver, Canada |
| 08/2017 | From Just Medicine to Pseudo-Personalized Medicine: Getting Closer, University of California San Francisco (UCSF), August 2017, San Francisco, CA |
| 05/2018 | Personalizing the Use of Post-Prostatectomy Radiotherapy, Wayne State- Department of Urology, May 2018, Detroit, MI |
| 06/2018 | Prognostic and Predictive Biomarkers in Prostate Cancer: Translational Biology, Dana Farber, June 2018, Boston, MA |
| 11/2018 | Prostate SBRT: Are we reaching the pinnacle of efficacy, toxicity, convenience, QOL, and cost?, Cleveland Clinic, November 2018, Cleveland, OH |
| 11/2019 | Disruptive Technologies in Prostate Cancer: Are you an Early or Late Adopter?, Queens University, November 2019, Kingston, Ontario, Canada |
| 02/2020 | Collaboration and Mentorship: Keys to a Successful Career, Cedars Sinai Medical Center, |
| 02/2020 | Collaboration and Mentorship: Keys to a Successful Career, Cedars Sinai Medical Center, February 2020, Los Angeles, CA |
| 02/2020 | The Need for Both Predictive and Ultra-Prognostic Biomarkers: Disrupting How We Treat Prostate Cancer, University of Colorado Cancer Center, Department of Radiation Oncology, February 2020, Denver, CO |
| 03/2020 | Closing the Evidence Gap in Biomarkers in Prostate Cancer, Thomas Jefferson University, March 2020, Philadelphia, PA |
| 03/2020 | Absolute versus Relative Risk: The Importance of Prognostic Biomarkers in Prostate Cancer, Duke University School of Medicine, March 2020, Durham, NC |
| 04/2020 | Leveraging Biology to Personalize Prostate Cancer Care (date moved due to Covid-19), University of Vienna, April 2020, Vienna, Austria |
| 05/2020 | Multi-National Collaborations for the Advancement of Prostate Cancer: Bringing the USA and Singapore Together (switched to virtual meeting), Singapore Health Services (SingHealth), May 2020, Singapore |
| 11/2020 | When Prognostic Biomarkers are Superior to Predictive Biomarkers: Challenging Dogma in Prostate Cancer, Sidney Kimmel Cancer Center, November 2020, Philadelphia, PA (Virtual) |
| 01/2021-present | Biomarker Driven Prostate Cancer Care: When Prognostic Biomarkers Surpass Predictive Biomarkers, Sunybrook, January 2021, Toronto, Canada |

01/2021-present When Prognostic Biomarkers are Superior to Predictive Biomarkers: The Role of UltraPrognostic Biomarkers in Prostate Cancer, Columbia University, January 2021, New York, NY, USA

Extramural Invited Presentations

1. Management of Spine Metastasis and Spine Radiosurgery, Department of Neurosurgery, University of Michigan, May 2014, Ann Arbor
2. Strategies to obtain your first faculty position, Prostate Cancer Foundation, October 2015, Washington D. C.
3. Impact of androgen receptor signaling on DNA repair and radiation resistance., The Centennial Conference of Urological Oncology. Memorial Sloan Kettering., October 2015, Waldorf Astoria, New York, NY
4. Contouring the Pelvic Nodes with Confidence, Practical Management Strategies and New Innovations in Prostate Radiotherapy, December 2016, New York City
5. Clinical Trial Data Sharing: Project Data Sphere and NRG, NRG GU Core Committee, January 2017, Dallas, TX
6. Personalizing Post-Prostatectomy Radiotherapy, Society of Urologic Oncology (SUO) Annual Meeting 2017, November 2017, Washington DC
7. Prognostic and Predictive Biomarkers in (Radiation) Oncology, FDA-AACR-ASTRO Regulatory Science and Policy Workshop, February 2018, Washington DC
8. Impact of Black Race on Prostate Cancer and Other-Cause Mortality, Prostate Cancer Foundation, October 2018, San Diego, CA
9. Treatment of Post-Operative Prostate Cancer, ASTRO Annual Meeting, 2018, October 2018, San Antonio, TX
10. Biomarkers: Utility of RNA in Radiation Oncology, ASTRO Annual Meeting, 2018, October 2018, San Antonio, TX
11. Genomic classification in localized disease, Global Summit on Genitourinary Malignancies, November 2018, Alberta, Canada
12. Optimal Use of Post-Operative Radiotherapy, Chicago Urological Society, December 2018, Chicago, IL
13. Keynote Presenter: The importance of biology and genetics in prostate cancer, COMPPARE, March 2019, Amelia Island, FL
14. NCTN Webinar: NRG GU006, National Clinical Trials Network, April 2019, Webinar
15. Role of Genomic Classifiers in Prostate Cancer, Minnesota Radiation Oncology, September 2019, Minneapolis, MN
16. Radiation Therapy for Prostate Cancer, Prostate Cancer Annual Advocacy Meeting, September 2019, Minneapolis, MN
17. Personalizing Post-Prostatectomy Radiotherapy, Donald Gleason Conference, September 2019, Minneapolis, MN
18. Improving the Quality of Post-Prostatectomy Radiotherapy, Michigan Urological Surgery Improvement Collaborative, October 2019, Livonia, MI
19. Prostate Cancer Radiotherapy Quality Collaborative, Michigan Radiation Oncology Quality Consortium (MROQC), October 2019, Livonia, MI
20. The role of brachytherapy boost in the management of high risk prostate cancer., URONCOR- Radiotherapy society of Spain, December 2019, Madrid, Spain
21. Adjuvant vs Salvage Radiotherapy and the Role of Hormone Therapy in Post-Prostatectomy Management, URONCOR- Radiotherapy society of Spain, December 2019, Madrid, Spain
22. The role of genomic biomarkers in localized and recurrent prostate cancer., URONCOR- Radiotherapy Society of Spain, December 2019, Madrid, Spain
23. NRG GU006 (BALANCE) Update, NRG Oncology, January 2020, Houston, TX
24. PCT Prostate SBRT: Is it ready for prime time?, Los Angeles Radiologic Society (LARS), January 2020, Los Angeles, CA
25. Study level surrogacy- A screening tool to identify surrogate endpoints, GU ASCO- ICECaP Study Group, February 2020, San Francisco
26. Genomic classifiers in prostate cancer: What is their role?, Los Angeles Radiologic Society (LARS), February 2020, Los Angeles Radiologic Society (LARS)

27. Timing of post-operative radiotherapy and addition of hormone therapy: Who, when, why, Los Angeles Radiologic Society (LARS), February 2020, Los Angeles, CA
28. Combination Brachytherapy: The Good, the Bad, and the Lack of Data (date moved due to Covid-19), European Society for Radiotherapy, May 2020, Vienna, Austria
29. GnRH agonist vs antagonists: Current state, Medscape, September 2020, Virtual
30. COVID-19 and Prostate Cancer, Prostate Cancer Foundation, September 2020, Virtual
31. Personalizing Prostate Cancer Care During COVID-19, UroToday, September 2020, Virtual
32. Genomic Biomarkers in Prostate Cancer (date changed due to Covid-19), XXII Congress of the Brazilian Society of Radiotherapy, November 2020, Salvador, Bahia, Brazil

Other

1. Meet the Expert: Prostate Cancer, ASTRO Annual Meeting, October 2018, San Antonio, TX
2. OncCOVID: Impact of COVID-19 on Cancer, Michigan Medicine Office of Development, Cancer Programs, June 2020, Virtual
3. Prostate Cancer Live Radio Q and A, KWRH St. Louis, September 2020, Radio

Seminars

1. Monitoring androgen receptor signaling in prostate cancer post radiation therapy with positron emission tomography, Imaging and Radiation Sciences (IMRAS) Symposium. Sloan Kettering Institute (SKI), May 2014, New York, NY
2. The Treatment of Spine Metastases and The University of Michigan Spine Oncology Program, University of Michigan, Department of Radiation Oncology, June 2016, Ann Arbor, MI
3. Vessel Sparing Radiation Therapy for the Treatment of Prostate Cancer, University of Michigan, Department of Radiation Oncology, July 2016, Ann Arbor, MI
4. Novel concepts using multi-modality treatment in high risk prostate cancer, Prostate Cancer SPORE- University of Michigan, November 2016, Ann Arbor, MI
5. The Molecular Subtypes of Prostate Cancer, Jim Montie Lecture Series- University of Michigan, November 2016, Ann Arbor, MI
6. Michigan Spine Oncology Program Overview for Breast Oncologists, University of Michigan, August 2019, Rogel Cancer Center
7. Androgen Receptor Activity in Localized Prostate Cancer, University of Michigan- Prostate Cancer SPORE, August 2019, Rogel Cancer Center
8. Prostate Cancer Live, ASTRO, September 2020, Virtual

Bibliography Peer-Reviewed Journals and Publications

1. Salvetti DJ, Sinha TK, Wilson KJ, Shay SD, **Spratt DE**, Mericle RA: An automated algorithm to improve the precision of basilar artery diameter measurements before and after subarachnoid hemorrhage-induced vasospasm in an animal model. *Neurosurgery* 66(1): 137-42, 2010. PM20023544
2. **Spratt DE**, Richardson M: Locked-in: listening to save a life. (Perspective). *Academic Medicine* 85(1): 62, 2010. PM20042824
3. **Spratt DE**, Diaz R, McElmurray J, Csiki I, Duggan D, Lu B, Delbeke D: Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer. *Clinical Nuclear Medicine* 35(4): 237-43, 2010. PM20305410
4. Passarella RJ, **Spratt DE**, van der Ende AE, Phillips JG, Wu H, Sathiyakumar V, Zhou L, Hallahan DE, Harth E, Diaz R: Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. *Cancer Res* 70(11): 4550-9, 2010. PM20484031
5. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, **Spratt DE**, Chung CH, Lu B: Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. *J Oncol* 2011: 941876, 2011. PM20981352
6. **Spratt DE**, Sakae M, Riaz N, Lok BH, Essandoh S, Hsu M, Zhang Z, Schupak K, Setton J, Lee NY: Time course and predictors for cancer-related fatigue in a series of oropharyngeal cancer patients treated with chemoradiation therapy. *Oncologist* 17(4): 569-76, 2012. PM22398160
7. Cox BW¹, **Spratt DE**¹, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y: International Spine

Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 83(5): e597-605, 2012. PM22608954

8. **Spratt DE**, Lee N: Current and emerging treatment options for nasopharyngeal carcinoma. *Onco Targets Ther* 5: 297-308, 2012. PM23118544
9. **Spratt DE**, Reddy VK, Choxi AA, Simon SD, Shay SD, Davidson MA, Barr FE, Summar ML, Mericle RA: Dexamethasone significantly attenuates sub-arachnoid hemorrhage-induced elevation in cerebrospinal fluid citrulline and leukocytes. *J Neurosurg Sci* 56(4): 363-71, 2012. PM23111298
10. **Spratt DE**, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ: Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 85(3): 686-92, 2013. PM22795805
11. Zumsteg ZS, **Spratt DE**, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ: Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. *Int J Radiat Oncol Biol Phys* 85(4): 1012-7, 2013. PM22981709
12. **Spratt DE**, Zumsteg Z, Ghadjar P, Pangasa M, Pei X, Fine SW, Yamada Y, Kollmeier M, Zelefsky MJ: Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis. *Int J Radiat Oncol Biol Phys* 85(5): 125461, 2013. PM23182392
13. Ghadjar P, Jackson A, **Spratt DE**, Oh JH, Munck af Rosenschöld P, Kollmeier M, Yorke E, Hunt M, Deasy JO, Zelefsky MJ: Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. *Eur Urol* 64(6): 931-8, 2013. PM23522772
14. Zumsteg ZS, **Spratt DE**, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. *Eur Urol* 64(6): 895-902, 2013. PM23541457
15. **Spratt DE**, Zhang Z, Zelefsky MJ: Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. (Letter to the Editor). *Eur Urol* 64(2): e29-30, 2013. PM23619389
16. **Spratt DE**, Scala LM, Folkert M, Voros L, Cohen GN, Happersett L, Katsoulakis E, Zelefsky MJ, Kollmeier MA, Yamada Y: A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. *Brachytherapy* 12(5): 428-33, 2013. PM23622710
17. Katsoulakis E, Solomon SB, Maybody M, Housman D, Niyazov G, Riaz N, Lovelock M, **Spratt DE**, Erinjeri JP, Thornton RH, Yamada Y: Temporary organ displacement coupled with image-guided, intensity-modulated radiotherapy for paraspinal tumors. *Radiat Oncol (London, England)* 8: 150, 2013. PM23800073
18. **Spratt DE**, Zelefsky MJ: Counterpoint: Combination therapy for intermediate risk prostate cancer. *Brachytherapy* 12(5): 398-9, 2013. PM23988508
19. **Spratt DE**, Zelefsky MJ: Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients. *Brachytherapy* 12(5): 389-92, 2013. PM23988506
20. Polkinghorn WR, Parker JS, Lee MX, Kass EM, **Spratt DE**, Iaquina PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL: Androgen receptor signaling regulates DNA repair in prostate cancers. *Cancer Discov* 3(11): 1245-53, 2013. PM24027196
21. **Spratt DE**, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ: Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. *Eur Urol* 63(4): 709-16, 2013. PM23287698
22. **Spratt DE**, Gordon Spratt E, Romanyshyn J, Wolden S, Patel S, Shah J, Shaha A, Pfister D, Keohan M, Lee NY: Radiation Therapy in the Treatment of Cutaneous Angiosarcoma of the Head and Neck. *World Journal of Surgical Medical and Radiation Oncology* 4: 1-2, 2013.
23. **Spratt DE**: Radiotherapy treatments for node-negative NPC. (Invited Commentary). *Lancet Oncol* 14(8): March, 2013.
24. Tam M, Riaz N, Salgado LR, **Spratt DE**, Katsoulakis E, Ho A, Morris LGT, Wong R, Wolden S, Rao S, Lee N: Distant metastasis is a critical mode of failure for patients with localized major salivary gland

tumors treated with surgery and radiation. *J Radiat Oncol* 2(3): 285-291, 2013. PM29152056 /PMC5687575

25. Salgado LR¹, **Spratt DE**¹, Riaz N, Romesser PB, Wolden S, Rao S, Chin C, Hong JC, Wong R, Lee NY: Radiation therapy in the treatment of minor salivary gland tumors. *Am J Clin Oncol* 37(5): 492-7, 2014. PM23428950
26. Katsoulakis E, Riaz N, Cannon DM, Goodman K, **Spratt DE**, Lovelock M, Yamada Y: Image-guided radiation therapy for liver tumors: gastrointestinal histology matters. *Am J Clin Oncol* 37(6): 561-7, 2014. PM23466584
27. Osborne JR, Green DA, **Spratt DE**, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS: A prospective pilot study of (89)Zr-J591 /prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. *J Urol* 191(5): 1439-45, 2014. PM24135437
28. Vlacich G¹, **Spratt DE**¹, Diaz R, Phillips JG, Crass J, Li CI, Shyr Y, Cmelak AJ: Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensitymodulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. *Radiother Oncol* 110(3): 435-40, 2014. PM24440043
29. **Spratt DE**, Salgado LR, Riaz N, Doran MG, Tam M, Wolden S, Katsoulakis E, Rao S, Ho A, Wong R, Lee NY: Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior? *Radio Oncol* 48(1): 56-61, 2014. PM24587780
30. **Spratt DE**, Folkert M, Zumsteg ZS, Chan TA, Beal K, Gutin PH, Pentsova E, Yamada Y: Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. *J Neurooncol* 116(2): 357-63, 2014. PM24190580
31. Ghadjar P, Zelefsky MJ, **Spratt DE**, Munck af Rosenschöld P, Oh JH, Hunt M, Kollmeier M, Happersett L, Yorke E, Deasy JO, Jackson A: Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 88(2): 339-44, 2014. PM24411606
32. **Spratt DE**, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR: Utility of FDG-PET in clinical neuroendocrine prostate cancer. *Prostate* 74(11): 1153-9, 2014. PM24913988
33. Romesser PB, Lim R, **Spratt DE**, Setton J, Riaz N, Lok B, Rao S, Sherman EJ, Schöder H, Lee NY: The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pretreatment [(18)F] fluorodeoxyglucose positron emission tomography scan. *Oral Oncol* 50(9): 802-8, 2014. PM25043882
34. Rimner A, **Spratt DE**, Zauderer MG, Rosenzweig KE, Wu AJ, Foster A, Yorke ED, Adusumilli P, Rusch VW, Krug LM: Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 90(2): 394-401, 2014. PM25073664
35. Doran MG, **Spratt DE**, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ: Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. *Molecular imaging* 13: n/a, 2014. PM25248353
36. **Spratt DE**, Gordon Spratt EA, Wu S, DeRosa A, Lee NY, Lacouture ME, Barker CA: Efficacy of skindirected therapy for cutaneous metastases from advanced cancer: a meta-analysis. *J Clin Oncol* 32(28): 3144-55, 2014. PM25154827
37. Doran MG, Watson PA, Cheal SM, **Spratt DE**, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS: Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. *J Nuc Med* 55(12): 2045-9, 2014. PM25453051
38. **Spratt DE**, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, Cohen G, Polkinghorn W, Yamada Y, Zelefsky MJ: Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. *BJU Int.* 114(3): 360-7, 2014. PM24447404
39. Doran MG, **Spratt DE**, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ: Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. *Mol Imaging* 13(8): 1-5, 2014. PM28650280
40. Zumsteg ZS, **Spratt DE**, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ: The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. *Eur Urol* 67(6): 1009-16, 2015. PM25308970

41. **Spratt DE**, Osborne JR: Disparities in castration-resistant prostate cancer trials. *J Clin Oncol* 33(10): 1101-3, 2015. PM25691679
42. **Spratt DE**, Zumsteg ZS, Pei X, Romesser PB, Yamada J, Kollmeier MA, Woo K, Zhang Z, Zelefsky MJ: Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. *Prostate* 75(2): 175-82, 2015. PM25327412
43. **Spratt DE**, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL: Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. *Cancer Res* 75(22): 4688-96, 2015. PM26432404/PMC4651750
44. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, **Spratt DE**, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J: PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. *Sci Transl Med* 7(283): 283ra51, 2015. PM25877889/PMC4433148
45. Zumsteg ZS, **Spratt DE**, Romesser PB, Pei X, Zhang Z, Kollmeier M, McBride S, Yamada Y, Zelefsky MJ: Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. *J Urol* 194(6): 1624-30, 2015. PM26165583
46. Taunk NK, **Spratt DE**, Bilsky M, Yamada Y: Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases. *J Natl Compr Canc Netw* 13(6): 801-9; quiz 809, 2015. PM26085394
47. Levis M, Guarneri A, Giaj Levra N, **Spratt DE**, Bartoncini S, Munoz F, Trino E, Botticella A, Arcadipane F, Ricardi U: Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy. *Tumori* 2016(3): 323-9, 2016. PM27002951
48. Doran MG, Carnazza KE, Steckler JM, **Spratt DE**, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ: Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. *Mol Pharm* 13(2): 683-8, 2016. PM26725682/PMC4738321
49. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, **Spratt DE**, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY: Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. *JAMA Oncol* 2(4): 471-80, 2016. PM26746117
50. Leeman JE, Bilsky M, Laufer I, Folkert MR, Taunk NK, Osborne JR, Arevalo-Perez J, Zatzky J, Alektiar KM, Yamada Y, **Spratt DE**: Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. *J Neurosurg Spine* 25(1): 52-8, 2016. PM26943256
51. Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylgeril V, Amir J, Chalasani S, Weber WA, **Spratt DE**, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR: Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. *EJNMMI Res* 6(1): 7, 2016. PM26801327/PMC4723373
52. **Spratt DE**, Beadle BM, Zumsteg ZS, Rivera A, Skinner HD, Osborne JR, Garden AS, Lee NY: The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. *Int J Radiat Oncol Biol Phys* 94(3): 523-31, 2016. PM26867881
53. Lee JY¹, **Spratt DE**¹, Liss AL, McLaughlin PW: Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. *Lancet Oncol* 17(5): e198-208, 2016. PM27301047
54. **Spratt DE**, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ: Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. *Eur Urol* 71(1): 37-43, 2016. PM27523595
55. Russell CM, Lebastchi AH, Borza T, **Spratt DE**, Morgan TM: The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. *Bladder Cancer* 2(4): 381-394, 2016. PM28035319 /PMC5181666
56. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, **Spratt DE**: Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. *Int J Radiat Oncol Biol Phys* 96(4): 770-777, 2016. PM27663760
57. Zhao SG, Chang SL, **Spratt DE**, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY: Development and validation of a 24-gene predictor of response to postoperative

- radiotherapy in prostate cancer: a matched, retrospective analysis. *Lancet Oncol* 17(11): 1612-1620, 2016. PM27743920
58. Zhu T, Chapman CH, Tsien C, Kim M, **Spratt DE**, Lawrence TS, Cao Y: Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. *Int J Radiat Oncol Biol Phys* 96(3): 696-705, 2016. PM27681767/PMC5117804
 59. **Spratt DE**, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY: Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. *Prostate Cancer Prostatic Dis* 19(3): 292-7, 2016. PM27215611
 60. Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, **Spratt DE**, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R: Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. *Ann Oncol* 27(9): 1706-12, 2016. PM27217541 /PMC4999561
 61. **Spratt DE**, Osborne JR, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ: Radium223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. *Prostate Cancer Prostatic Dis* 19(3): 271-6, 2016. PM27112529
 62. **Spratt DE**, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL: Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. *Eur Urol Focus* 2(5): 532-539, 2016. PM28723519
 63. Gadia R, Teixeira Leite ET, Bierrenbach AL, Ynoe de Moraes F, **Spratt DE**, Arruda FF, Cintra Vita Abreu CE, Fernandes da Silva JL, de Andrade Carvalho H, Garicochea B: Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. *Adv Radiat Oncol* 1(4): 300-309, 2016. PM28740901 /PMC5514229
 64. **Spratt DE**, Zaki BI, Franc BL, Hartford AC, Osborne JR: ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. *Clin Nucl Med* 41(2): 106-17, 2016. PM26646993
 65. **Spratt DE**, Arevalo-Perez J, Leeman JE, Gerber NK, Folkert M, Taunk NK, Alektiar KM, Karimi S, Lyo JK, Tap WD, Bilsky MH, Laufer I, Yamada Y, Osborne JR: Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. *Spine J* 16(3): 291-8, 2016. PM26325017/PMC5665020
 66. **Spratt DE**, Wu AJ, Adeseye V, Din SU, Shaikh F, Woo KM, Zhang Z, Foster A, Rosenzweig KE, Gewanter R, Huang J, Rimner A: Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. *Clin Lung Cancer* 17(3): 177-83, 2016. PM26602271/26602271
 67. **Spratt DE**, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR: Racial/Ethnic Disparities in Genomic Sequencing. *JAMA Oncol* 2(8): 1070-4, 2016. PM27366979/PMC5123755
 68. Cole AI, Morgan TM, **Spratt DE**, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R: Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. *J Urol* 196(2): 405-11, 2016. PM26920466
 69. **Spratt DE**, Szerlip N: Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent? (Letter to the Editor). *J Clin Oncol* 34(22): 2677, 2016. PM27325845
 70. **Spratt DE**, Zumsteg ZS, Feng FY, Tomlins SA: Translational and clinical implications of the genetic landscape of prostate cancer. *Nat Rev Clin Oncol* 13(10): 597-610, 2016. PM27245282/PMC5030163
 71. **Spratt DE**: Salvage Radiotherapy After Prostatectomy: Two Sides of the Coin. (Invited Editorial). *Eur Urol* 70(5): 758-59, 2016. PM27025588
 72. **Spratt DE**, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess R, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM: Independent Surgical Validation of the New Prostate Cancer Grade Grouping System. *BJU Int.* 118(5): 763-69, 2016. PM27009882
 73. **Spratt DE**, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ: American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. *Brachytherapy* 16(1): 1-12, 2017. PM27771243

74. Soliman M, Taunk NK, Simons RE, Osborne JR, Kim MM, Szerlip NJ, **Spratt DE**: Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. *Neurosurg Focus* 42(1): E5, 2017. PM28041315
75. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, **Spratt DE**, Sandler HM, Freedland SJ: Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. *Prostate* 77(2): 154-163, 2017. PM27683213
76. **Spratt DE**, Wahl DR, Lawrence TS: Genomic-adjusted radiation dose. (Letter to the Editor). *Lancet Oncol* 18(3): e127, 2017. PM28271860
77. **Spratt DE**, Jaggi R: Breast and Prostate Cancer: Lessons to Be Shared. *Int J Radiat Oncol Biol Phys* 98(2): 263-268, 2017. PM28463142
78. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezoslosky MD, Vastola ME, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, **Spratt DE**, Hoffman KE, Feng FY, Nguyen PL: National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. *Int J Radiat Oncol Biol Phys* 98(2): 338-343, 2017. PM28463152
79. Wang ML, McHugh JB, Weizer AZ, Morgan TM, Chinnaiyan AM, Sciallis AP, Lagstein A, **Spratt DE**, Mehra R: Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. *Urol Case Rep* 13: 154-157, 2017. PM28567335/PMC5443920
80. Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, **Spratt DE**: Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. *Curr Urol Rep* 18(7): 55, 2017. PM28589403
81. Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, **Spratt DE**, Simons JW, Pienta KJ, Soule HR: Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. *Prostate* 77(15): 14781488, 2017. PM28925066
82. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, **Spratt DE**, Sandler HM, Freedland SJ: Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. *Prostate* 77(16): 15921600, 2017. PM28994485/PMC5685668
83. Costas-Muniz R, Amir J, Paris M, Spratt D, Arevalo-Perez J, Fareedy S, González CJ, Gany F, CamachoRivera M, Osborne JR: Interventional Cultural and Language Assistance Program: Associations between Cultural and Linguistic Factors and Satisfaction with Cancer Care. *J Community Med Health Educ* 7(1): 2017. PM29423339/PMC5800524
84. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, **Spratt DE**, Wahl DR, Pierce LJ, Feng FY: Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. *NPJ Breast Cancer* 3: 29, 2017. PM28840192/PMC5562815
85. Shen J, Wang L, Daignault S, **Spratt DE**, Morgan TM, Taylor JMG: Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap. *J Biopharm Stat* 1: 1-20, 2017. PM28934002
86. **Spratt DE**, Lee JY, Dess RT, Narayana V, Evans C, Liss A, Winfield R, Schipper MJ, Lawrence TS, McLaughlin PW: Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. *Eur Urol* 72(4): 617-24, 2017. PM28233591
87. Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng FY, Morgan TM, Desai N, **Spratt DE**: 'Very Early' Salvage Radiotherapy Improves Distant Metastasis-Free Survival. *J Urol* 197(3 pt 1): 662-68, 2017. PM27614333
88. Kerbauy MN, Moraes FY, Lok BH, Ma J, Kerbauy LN, **Spratt DE**, Santos FP, Perini GF, Berlin A, Chung C, Hamerschlag N, Yahalom J: Challenges and opportunities in primary CNS lymphoma: A systematic review. *Radiother Oncol* 122(3): 352-61, 2017. PM28104300
89. **Spratt DE**, Zelefsky MJ: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field Design. *Eur Urol* 71(4): e123-e124, 2017. PM27836418
90. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, **Spratt DE**: Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. *Cancer* 123(9): 1635-42, 2017. PM28001303
91. **Spratt DE**, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LL, du Plessis M, Choerung V, Haddad Z, Buerki C, Davicioni E,

- Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY: Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. *J Clin Oncol* 35(18): 1991-98, 2017. PM28358655/PMC6530581
92. Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, **Spratt DE**: External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. *Brachytherapy* 16(4): 782-89, 2017. PM28499487
 93. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, **Spratt DE**: Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. *Int J Radiat Oncol Biol Phys* 98(4): 726-32, 2017. PM28258894
 94. Green M, Feng FY, Mehra R, **Spratt DE**: Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. *Immunotherapy* 9(9): 695-99, 2017. PM28771102
 95. Jackson WC, Desai N, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, **Spratt DE**: Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-Prostatectomy Salvage Radiation Therapy: A Multi-Institutional Study. *BJU Int.* 120(3): 351-57, 2017. PM28139024
 96. Yang DD, Muralidhar V, Mahal BA, Nezoslosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, **Spratt DE**, Hoffman KE, Feng FY, Nguyen PL: Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. *Urol Oncol* 35(9): 524.e25-e32, 2017. PM28533151
 97. **Spratt DE**: Performance and Utility of Prognostic Genomic Biomarkers After Prostatectomy: Decipher-ing the Data. (Invited Editorial). *J Clin Oncol* 35(25): 2977-78, 2017. PM28682686
 98. Udager AM, McHugh JB, Morgan TM, **Spratt DE**, Chinnaiyan AM, Mehra R: Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. *Appl Immunohistochem Mol Morphol* 27(5): 392, 2017. PM28968266/PMC5876063
 99. Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, **Spratt DE**, Jiang H, Mehra R: Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus* 3(4-5): 502-09, 2017. PM28753826
 100. **Spratt DE**: To ProtecT Our Patients With Prostate Cancer. *JAMA Oncol* 3(11): 1461-62, 2017. PM28301652
 101. Zumsteg ZS, Zelefsky MJ, Woo KM, **Spratt DE**, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z: Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer. *BJU Int* 120(5B): E87-E95, 2017. PM28464446
 102. Nguyen PL, Haddad Z, Ross AE, Martin NE, Dehesi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, **Spratt DE**, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA: Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. *Eur Urol* 72(5): 845-52, 2017. PM28528811
 103. **Spratt DE**: Convergence of Genomic Instability and SChLAP1: Weathering the Storm of Intraductal Carcinoma of the Prostate. (Invited Editorial). *Eur Urol* 72(5): 675-76, 2017. PM28528812
 104. Suresh K, Taylor JMG, **Spratt DE**, Daignault S, Tsodikov A: Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model. *Biom J* 59(6): 1277-1300, 2017. PM28508545/PMC5957493
 105. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, **Spratt DE**, Goodrich DW, Eng KH, Ellis L: TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. *Clin Cancer Res* 23(22): 7072-83, 2017. PM28899973
 106. Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, **Spratt DE**, Weber WA, Larson SM, Pillarsetty NVK: Repeatability of [⁶⁸Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. *Mol Imaging Biol* 19(6): 944-51, 2017. PM28534214/PMC5664162
 107. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM,

- Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, **Spratt DE***, Feng FY*: Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. *JAMA Oncol* 3(12): 1663-72, 2017. PM28494073/PMC5824281
108. **Spratt DE**, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ, Younge KC, Bilsky M, Park P, Szerlip NJ: An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report *Lancet Oncol* 18(12): e720-e730, 2017. PM29208438
 109. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, **Spratt DE**: Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer. *BJU Int* 121(1): 61-8, 2018. PM28710895
 110. Smith BW, Joseph JR, Saadeh YS, La Marca F, Szerlip NJ, Schermerhorn TC, **Spratt DE**, Younge KC, Park P: Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature. *World Neurosurg* 109: e502-e509, 2018. PM29038086
 111. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, **Spratt DE***, Hamstra DA*: A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. *Pract Radiat Oncol* 8(1): 40-47, 2018. PM29304991
 112. **Spratt DE**, Mancini BR, Hayman JA, Boike T, Pierce LJ, Moran JM, Dominello MM, Fireman M, Griffith K, Jolly S, Michigan Radiation Oncology Quality Consortium.: Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis. *Int J Radiat Oncol Biol Phys* 101(2): 462-467, 2018. PM29726364
 113. **Spratt DE**: Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer. (Invited Editorial). *Int J Radiat Oncol Biol Phys* 101(3): 513-515, 2018. PM29893267
 114. Lalani N, Griffith KA, Jones RD, **Spratt DE**, Croke J, Jaggi R: Mentorship Experiences of Early-Career Academic Radiation Oncologists in North America. *Int J Radiat Oncol Biol Phys* 101(3): 732-740, 2018. PM29893281
 115. Raman S, Moraes FY, Mendez LC, Taunk NK, Suh JH, Souhami L, Slotman B, Kongkham P, **Spratt DE**, Berlin A, Marta GN: The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. *J Neurooncol* 139(1): 195-203, 2018. PM29869023
 116. Kornberg Z, Cooperberg MR, **Spratt DE**, Feng FY: Genomic biomarkers in prostate cancer. *Transl Androl Urol* 7(3): 459-471, 2018. PM30050804/PMC6043739
 117. Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, **Spratt DE**, Feng FY, Trinh QD, Nguyen PL: Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. *Ann Oncol* 29(2): 386-391, 2018. PM29267861
 118. **Spratt DE**: Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 102(3): 556-560, 2018. PM30238901
 119. Rosenstein BS, Rao A, Moran JM, **Spratt DE**, Mendonca MS, Al-Lazikani B, Mayo CS, Speers C: Genomics, bio specimens, and other biological data: Current status and future directions. *Med Phys* 45(10): e829-e833, 2018. PM30226926/PMC6214357
 120. Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, **Spratt DE**: Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancerspecific Mortality: Competition Between Age and Time to Biochemical Failure. *Eur Urol Oncol* 1(4): 276282, 2018. PM31100248
 121. **Spratt DE**, Feng FY: Primum Non Nocere: Adding Hormone Therapy to Early Salvage Radiotherapy Makes the Physician Feel Better, But Does It Help the Patient? (Letter to the Editor). *Eur Urol Oncol* 1(4): 323-324, 2018. PM31100255
 122. Hu JC, Tosoian JJ, Qi J, Kaye D, Johnson A, Linsell S, Montie JE, Ghani KR, Miller DC, Wojno K, Burks FN, **Spratt DE**, Morgan TM: Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. *JCO Precis Oncol* 2: ahead of print, 2018. PM32832833/PMC7440129
 123. Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, **Spratt DE**, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA: Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. *Med Oncol* 35(12): 152, 2018. PM30291535

124. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, **Spratt DE**, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. *JAMA* 319(9): 896-905, 2018. PM29509865
125. Younge KC, Marsh RB, Owen D, Geng H, Xiao Y, **Spratt DE**, Foy J, Suresh K, Wu QJ, Yin FF, Ryu S, Matuszak MM: Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. *Int J Radiat Oncol Biol Phys* 100(4): 10671074, 2018. PM29485048
126. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, **Spratt DE**, Yu JB, Orio PF 3rd, Nguyen PL: Travel distance and stereotactic body radiotherapy for localized prostate cancer. *Cancer* 124(6): 1141-1149, 2018. PM29231964
127. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, **Spratt DE**, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU: Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. *Int J Radiat Oncol Biol Phys* 101(4): 883-888, 2018. PM29976500
128. **Spratt DE**, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choerung V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. *J Clin Oncol* 36(6): 581-590, 2018. PM29185869
129. **Spratt DE**, McHugh DJ, Morris MJ, Morgans AK: Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. (Review). *Am Soc Clin Oncol Educ Book* (38): 355-362, 2018. PM30231323
130. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, **Spratt DE**, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* 174(3): 758-769.e9, 2018. PM30033370
131. Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, **Spratt DE**, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C: Medulloblastoma therapy generates risk of a poorlyprognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. *Acta Neuropathol Commun* 6(1): 67, 2018. PM30049282/PMC6062866
132. **Spratt DE**, Suresh K, Osawa T, Schipper M, Jackson WC, Abugharib A, Lebastchi A, Smith D, Montgomery JS, Palapattu GS, Priya Kunju L, Wu A, Lew M, Tomlins SA, Chinnaiyan AM, Weizer AZ, Hafez KS, Kaffenberger SD, Udager A, Mehra R: Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. *Med Oncol* 35(3): 21, 2018. PM29387987
133. **Spratt DE**, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY: A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. *Eur Urol* 73(2): 15665, 2018. PM28716370
134. Moraes FY, Mendez LC, Taunk NK, Raman S, Suh JH, Souhami L, Slotman B, Weltman E, **Spratt DE**, Berlin A, Marta GN: Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. *J Neurooncol* 136(3): 585-93, 2018. PM29164521

135. Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, **Spratt DE***, Desai NB*: Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study. *BJU Int* 121(3): 356-72, 2018. PM28581200
136. **Spratt DE**, Dess RT, Feng FY: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet. (Letter to the Editor). *Eur Urol* 73(3): e64-e65, 2018. PM29111144
137. Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JW, Schipper MJ, **Spratt DE**: Changes in Prostate Orientation Due to Removal of a Foley Catheter. *Med Phys* 45(4): 1369-78, 2018. PM29474748
138. Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, **Spratt DE**, Cao Y, Lawrence TS, Kim MM: Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. *J Neurooncol* 138(1): 15562, 2018. PM29388034
139. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, **Spratt DE**, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA: Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncol* 4(5): e175230, 2018. PM29372236/PMC5885162
140. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, **Spratt DE**: Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* 101(2): 376-86, 2018. PM29487023
141. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, **Spratt DE**, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD: Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. *Eur Urol* 74(1): 99-106, 2018. PM29128208
142. **Spratt DE**, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW: Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. *Eur Urol* 74(1): 107-114, 2018. PM29233664
143. Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, **Spratt DE**, Davicioni E, Sboner A, Barbieri CE: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. *JCO Precis Oncol* 10.1200/PO.18.00036: 1-13, 2018. PM30761387/PMC6370327
144. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, **Spratt DE**, Den RB, Martin NE, Mouw KW, Orto PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL: Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. *Eur Urol* 74(2): 146-54, 2018. PM29478736/PMC6615042
145. Siegel GW, Biermann JS, Calinescu AA, **Spratt DE**, Szerlip NJ: Surgical Approach to Bone Metastases. *Curr Osteoporos Rep* 16(4): 512-18, 2018. PM29915966
146. Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, **Spratt DE**, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM: Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. *Clin Cancer Res* 24(16): 3908-16, 2018. PM29760221/PMC6512950
147. **Spratt DE**, Carroll PC: Reply to A.J. Chang et al and A. Gomez-Iturriaga et al. (Invited Commentary Reply). *J Clin Oncol* epub: JCO1800799, 2018. PM30212290
148. Moraes FY, Leite ET, Hamstra DA, Feng FY, Arruda FF, Gadia R, Abreu CE, Marta GN, Hanna SA, Silva JL, Carvalho HA, **Spratt DE**: Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. *Am J Clin Oncol* 41(1): 6-12, 2018. PM26703812
149. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, **Spratt DE**: Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. *Eur Urol* 74(4): 413-19, 2018. PM29306514

150. **Spratt DE**, Schaeffer EM: Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. (Invited Editorial). *Eur Urol* 74(4): 453-54, 2018. PM29907357
151. Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, **Spratt DE**, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R: Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. *Eur Urol* 74(4): 52931, 2018. PM29980330
152. **Spratt DE**: Are we inadvertently widening the disparity gap in pursuit of precision oncology? (Invited Editorial). *Br J Cancer* 119(7): 783-784, 2018. PM30131549
153. **Spratt DE**, Carroll PR: Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy? *J Clin Oncol* 36(29): 2914-17, 2018. PM29782208
154. Guo M, Kolberg KL, Smith EC, Smith BW, Yousif JE, Kessler JL, Linzey JR, Calinescu AA, Clines GA, **Spratt DE**, Szerlip NJ: Predominance of Spinal Metastases Involving the Posterior Vertebral Body. *World Neurosurg* 119: e991-e996, 2018. PM30114534
155. Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, **Spratt DE**, Morgan TM, Davenport MS, Chinnaiyan AM, Cyra J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS: Transcriptomic heterogeneity in multifocal prostate cancer. *JCI Insight* 3(21): e123468, 2018. PM30385730/PMC6238741
156. Yang DD, Mahal BA, Muralidhar V, Nezoslosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF Rd, Beard CJ, Hoffman KE, Trinh QD, **Spratt DE**, Feng FY, Nguyen PL: Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. *Eur Urol Focus* 5(1): 69-76, 2019. PM28753811
157. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, **Spratt DE**, Kupelian PA, Steinberg ML, King CR: Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. *JAMA Oncol* 5(1): 91-6, 2019. PM30326032 /PMC6440243
158. Christensen RE, Nause-Osthoff RC, Waldman JC, **Spratt DE**, Hearn JWD: Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative. *Paediatr Anaesth* 29(3): 265-270, 2019. PM30580487
159. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, **Spratt DE**, Feng FY, Nguyen PL: Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. *Eur Urol* 75(1): 35-41, 2019. PM30554605
160. Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, **Spratt DE**, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R: Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. *Hum Pathol* 86: 76-84, 2019. PM30537495
161. **Spratt DE**: Combination therapies in prostate cancer: proceed with caution. (Invited Editorial). *Lancet Oncol* 20(3): 321-323, 2019. PM30738781
162. Beeler WH, Paradis KC, Gemmete JJ, Chaudhary N, Kim MM, Smith SR, Paradis E, Matuszak MM, Park 162. Beeler WH, Paradis KC, Gemmete JJ, Chaudhary N, Kim MM, Smith SR, Paradis E, Matuszak MM, Park P, Archer PG, Szerlip NJ, **Spratt DE**: Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging Registration to Delineate the Spinal Cord During Spine Stereotactic Radiosurgery. *World Neurosurg* 122: e655-e666, 2019. PM30992117
163. Beesley LJ, Morgan TM, **Spratt DE**, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG: Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. *JAMA Netw Open* 2(2): e187765, 2019. PM30707231
164. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, **Spratt DE**, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR: Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. *JAMA Netw Open* 2(2): e188006, 2019. PM30735235
165. Zumsteg ZS, **Spratt DE**: Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification? (Invited Editorial). *Int J Radiat Oncol Biol Phys* 103(1): 92-94, 2019. PM30563670
166. Kishan AU, Hall WA, **Spratt DE**: Comparing Apples to Oranges: A Self-fulfilling Prophecy? (Letter to the Editor). *Eur Urol* 75(5): e133-e134, 2019. PM30670312

167. Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, **Spratt DE**: STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer? *Int J Radiat Oncol Biol Phys* 104(1): 33-35, 2019. PM30967237
168. Simon CT, Skala SL, Magers MJ, Weizer A, Kaffenberger SD, Chinnaiyan AM, **Spratt DE**, Montgomery J, Mehra R, Lew M: The utility of upper urinary tract urine cytology before and after application of the Paris system. *Diagn Cytopathol* 47(5): 421-427, 2019. PM30569543
169. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, **Spratt DE**, Srinivas S, Tward J, Shead DA, Freedman-Cass DA: Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 17(5): 479-505, 2019. PM31085757
170. Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, **Spratt DE**, Sabra M, Larson SM, Grewal RK: Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort. *Clin Nucl Med* 44(7): 544-549, 2019. PM31107749
171. Kishan AU, Wang C, Steinberg ML, **Spratt DE**: Key considerations when reviewing subsequent primary cancers following radiotherapy. (Letter to the Editor). *Lancet Oncol* 20(6): e291, 2019. PM31162098
172. Soni PD, **Spratt DE**: Population-Based Observational Studies in Oncology: Proceed With Caution. (Invited Review). *Semin Radiat Oncol* 29(4): 302-305, 2019. PM31472729
173. Mitin T, Henry A, Choudhury A, Chen RC, Pinkawa M, **Spratt DE**: SBRT for Localized Prostate Cancer: Is it Ready for Take-Off? (Invited Editorial). *Int J Radiat Oncol Biol Phys* 105(3): 618-620, 2019. PM31540596
174. Vince RA Jr, Tosoian JJ, Jackson WC, **Spratt DE**, Morgan TM: Tissue-based genomics: which test and when. *Curr Opin Urol* 29(6): 598-604, 2019. PM31584886
175. Taylor AS, **Spratt DE**, Dhanasekaran SM, Mehra R: Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. *Arch Pathol Lab Med* 143(12): 1477-1491, 2019. PM31765248
176. Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, **Spratt DE**, Liauw S, Hamstra D: Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. *Am J Clin Oncol* 42(4): 382390, 2019. PM30724780
177. Salami SS, Singhal U, **Spratt DE**, Palapattu GS, Hollenbeck BK, Schonhoft JD, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Tomlins SA, Dittamore R, Feng FY, Morgan TM: Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. *JCO Precis Oncol* 3: ahead of print, 2019. PM32832835/PMC7440257
178. Weindorf SC, Taylor AS, Kumar-Sinha C, Robinson D, Wu YM, Cao X, **Spratt DE**, Kim MM, Lagstein A, Chinnaiyan AM, Mehra R: Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion. *Med Oncol* 36(3): 27, 2019. PM30712214
179. Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, **Spratt DE**, Reichert Z, Palapattu GS, Taichman RS, Tomlins SA, Morgan TM: Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. *Neoplasia* 21(8): 802-809, 2019. PM31276932/PMC6612010
180. Paradis KC, Mayo C, Owen D, **Spratt DE**, Hearn J, Rosen B, Kashani R, Moran J, Tatro DS, Beeler W, Vineberg K, Smith DC, Matuszak MM: The Special Medical Physics Consult Process for Reirradiation Patients. *Adv Radiat Oncol* 4(4): 559-565, 2019. PM31681862/PMC6817723
181. Soni PD, Hartman HE, Schipper MJ, **Spratt DE**: Reply to J.R. Rider et al. (Invited Commentary Reply). *J Clin Oncol* 37(29): 2696-2697, 2019. PM31465259
182. Kishan AU, Chu FI, King CR, Seiferheld W, **Spratt DE**, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM: Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. *Eur Urol* 77(2): 201-08, 2019. PM31718822
183. Salami SS, Kaplan JB, Nallandhighal S, Takhar M, Tosoian JJ, Lee M, Yoon J, Hovelson DH, Plouffe KR, Kaffenberger SD, Schaeffer EM, Karnes RJ, Lotan TL, Morgan TM, George AK, Montgomery JS, Davenport MS, You S, Tomlins SA, Curci NE, Kim HL, **Spratt DE**, Udager AM, Palapattu GS: Biologic

Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. *JCO Precis Oncol* 3: ahead of print, 2019. PM32914029/PMC7446477

184. Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, **Spratt DE**, Hung AY, Antonarakis ES, Tran PT: A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). *BMC Cancer* 19(1): 572, 2019. PM31196032/PMC6567492
185. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, **Spratt DE**, Nguyen PL, Maher CA, Small EJ, Feng FY: Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. *Clin Cancer Res* 25(8): 2450-2457, 2019. PM30573691
186. **Spratt DE**, Michalski JM: Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. (Invited Editorial). *Int J Radiat Oncol Biol Phys* 104(4): 798-800, 2019. PM31204661
187. **Spratt DE**, Speers C: RadioGx: A New Preclinical Tool to Model Intrinsic Radiosensitivity. (Invited Editorial). *Cancer Res* 79(24): 6076-6078, 2019. PM31836601
188. Kennedy JM, Wang X, Plouffe KR, Dhanasekaran SM, Hafez K, Palapattu GS, Else T, Weizer AZ, Morgan TM, **Spratt DE**, Davenport MS, Chinnaiyan AM, Udager AM, Mehra R: Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. *Med Oncol* 36(9): 74, 2019. PM31332543
189. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezoslosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, **Spratt DE**, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA: Active Surveillance for Low-Risk Prostate Cancer in Black Patients. *N Engl J Med* 380(21): 2070-2072, 2019. PM31116925
190. Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, **Spratt DE**, Ellis L, Jaffe JD, D'Amico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M: High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. *Nat Commun* 10(1): 4358, 2019. PM31554818/PMC6761092
191. Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, **Spratt DE**: International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy. *J Urol* 201(2): 284-91, 2019. PM30153435
192. Wang C, Raldow AC, Nickols NG, Nguyen PL, **Spratt DE**, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU: Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with Highgrade Prostate Cancer. *Eur Urol Oncol* EUO-172: 1-4, 2019. PM31411981
193. Mahal BA, Butler S, Franco I, **Spratt DE**, Rebbeck TR, D'Amico AV, Nguyen PL: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. *JAMA* 321(7): 704-06, 2019. PM30743264/PMC6439610
194. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, **Spratt DE**, Feng FY: The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *J Natl Cancer Inst* 111(3): 301-310, 2019. PM30321406
195. Zaorsky NG, **Spratt DE**, Blanchard P: External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Populationbased Analysis. *Eur Urol*. (Letter to the Editor). *Eur Urol* 75(4): e98-e99, 2019. PM30473434
196. Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, Zietman AL, Jagsi R, Schipper MJ, **Spratt DE**: Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. *J Clin Oncol* 37(14): 1209-16, 2019. PM30897037/PMC7186578
197. Zhao SG, Yu M, **Spratt DE**, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR: Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. *Neuro Oncol* 21 (9): 1141-49, 2019. PM31121035/PMC6736132 (available on 2020-09-06)

198. Mahal BA, Alshalalfa M, **Spratt DE**, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW: Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. *Eur Urol* 75(6): 1038-40, 2019. PM30683576
199. Kim MM, Speers C, Li P, Schipper M, Junck L, Leung D, Orringer D, Heth J, Umemura Y, **Spratt DE**, Wahl DR, Cao Y, Lawrence TS, Tsien CI: Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. *J Neurooncol* 143(2): 313-19, 2019. PM30977058
200. Weiner AB, Ko OS, Zhu A, **Spratt DE**, Hu JC, Schaeffer EM: National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. *Urol Oncol* 37(6): 353.e1-353.e8, 2019. PM30611643/PMC6511330 (available on 2020-06-01)
201. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, **Spratt DE**: Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. *JAMA Oncol* 5(7): 975-83, 2019. PM31120534/PMC6547116
202. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, **Spratt DE**: Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. *Int J Radiat Oncol Biol Phys* 104(4): 778-89, 2019. PM30959121/PMC6770993
203. Hawken SR¹, **Spratt DE**¹, Qi J, Linsell SM, Cher ML, Ghani KR, Miller DC, Montie JE, Morgan TM, Michigan Urological Surgery Improvement Collaborative.: Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. *Int J Radiat Oncol Biol Phys* 104(5): 1030-34, 2019. PM30682490
204. Das S, Salami SS, **Spratt DE**, Kaffenberger SD, Jacobs MF, Morgan TM: Bringing prostate cancer germline genetics into clinical practice. *J Urol* 202(2): 223-30, 2019. PM30730411
205. Elder JB, Sherman JH, Prevedello DM, Szerlip NJ, **Spratt DE**, Shaikhouni A, Mohyeldin A, Perez-Roman RJ, Buttrick SS, Ali SC, Komotar RJ, Todeschini A, Shahein M, Revuelta JM, Hardesty D, Carrau RL, Zada G, Giannotta S, Dornbos D, Lonser RR: Tumor. *Oper Neurosurg (Hagerstown)* 17(S2): S119-S152, 2019. PM31099848
206. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, **Spratt DE**, Taneja SS, Penson DF: The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. *Eur Urol* 76(3): 268-72, 2019. PM31128968
207. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efsthathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, **Spratt DE**: The current state of randomized clinical trial evidence for prostate brachytherapy. *Urol Oncol* 37(9): 599-10, 2019. PM31060795
208. Gharzai LA, Green MD, Griffith KA, Else T, Mayo CS, Hesseltine E, **Spratt DE**, Ben-Josef E, Sabolch A, Miller BS, Worden F, Giordano TJ, Hammer GD, Jolly S: Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. *J Clin Endocrinol Metab* 104(9): 3743-50, 2019. PM31220287
209. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf D, He HH, Speers C, **Spratt DE**, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY: DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway. *Clin Cancer Res* 25(18): 5608-22, 2019. PM31266829/PMC6744969
210. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, **Spratt DE**, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA: Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. *Cancer* 125(19): 3338-46, 2019. PM31251398
211. Saadeh YS, Elswick CM, Fateh JA, Smith BW, Joseph JR, **Spratt DE**, Oppenlander ME, Park P, Szerlip NJ: Analysis of Outcomes Between Traditional Open versus Mini-Open Approach in Surgical Treatment of Spinal Metastasis. *World Neurosurg* 130: e467-e474, 2019. PM31247354
212. Dess RT, Mahal BA, **Spratt DE**: Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer. (Invited Commentary Reply). *JAMA Oncol* epub: ahead of print, 2019. PM31670754

213. Gharzai LA, Beeler WH, Hayman JA, Mancini B, Jagsi R, Pierce L, Moran JM, Dominello MM, Boike T, Griffith K, Jolly S, **Spratt DE**, Michigan Radiation Oncology Quality Consortium.: Recommendations for single fraction radiation therapy and stereotactic body radiation therapy in palliative treatment of bone metastases: A statewide practice patterns survey. *Pract Radiat Oncol* 9(6): e541-e548, 2019. PM31326530
214. **Spratt DE**: Seeking Consistency in Guidelines: Level of Evidence, Trial Endpoints, and Personalized Recommendations. *Pract Radiat Oncol* 9(6): 496-500, 2019. PM31279067
215. Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, **Spratt DE**, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU: Multi-institutional Analysis of Prostate Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT). *Int J Radiat Oncol Biol Phys* 105(3): 628-36, 2019. PM31276777
216. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, **Spratt DE**, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL: Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. *Int J Radiat Oncol Biol Phys* 105(3): 621-27, 2019. PM31271825
217. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, **Spratt DE**, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY: Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. *Eur Urol Oncol* 2(6): 685-90, 2019. PM31411984
218. **Spratt DE**: The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy. (Invited Editorial). *Eur Urol* 76(5): 596-98, 2019. PM31378435
219. **Spratt DE**, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM: Transcriptomic heterogeneity of androgen receptor (AR) activity defines a *de novo* low AR-active subclass in treatment naïve primary prostate cancer. *Clin Cancer Res* 25(22): 6721-30, 2019. PM31515456/PMC6858964
220. Dharmarajan KV, Walters CB, Levin TT, Milazzo CA, Monether C, Rawlins-Duell R, Tickoo R, **Spratt DE**, Lovie S, Giannantoni-Ibelli G, McCormick B: A Video Decision Aid Improves Informed Decision Making in Patients With Advanced Cancer Considering Palliative Radiation Therapy. *J Pain Symptom Manage* 58(6): 1048-55, 2019. PM31472276
221. Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, **Spratt DE**, Vidal AC, Lin D, Hitchins MP, You S, Freeman MR, Yamoah K, Davicioni E, Freedland SJ: Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. *Prostate Cancer Prostatic Dis* epub: ahead of print, 2019. PM31844180
222. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, **Spratt DE**, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU: Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. *Eur Urol* 77(1): 3-10, 2020. PM30992160
223. Glicksman RM, Tjong MC, Neves-Junior WFP, **Spratt DE**, Chua KLM, Mansouri A, Chua MLK, Berlin A, Winter JD, Dahele M, Slotman BJ, Bilsky M, Shultz DB, Maldaun M, Szerlip N, Lo SS, Yamada Y, Vera-Badillo FE, Marta GN, Moraes FY: Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases *JAMA Oncol* 7(4): 567, 2020. PM31895403
224. Birer S, **Spratt DE**: Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. (Letter to the Editor). *Lancet Oncol* 21(1): e12, 2020. PM31908298
225. Taylor AS, Morgan TM, Wallington DG, Chinnaiyan AM, **Spratt DE**, Mehra R: Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. *Prostate* 80(2): 146-152, 2020. PM31737920
226. Moraes FY, Chen X, Yan M, **Spratt DE**, Redmond K, Jackson WC, Yamada YJ: Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases: Defining Dose and Dose Constraints. *Neurosurg Clin N Am* 31(2): 167-189, 2020. PM32147009

227. Nagar H, **Spratt DE**: Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy? (Invited Editorial). *Int J Radiat Oncol Biol Phys* 107(2): 297-298, 2020. PM32386737
228. Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, **Spratt DE**: Prostate Cancer Radiotherapy Recommendations in Response to COVID-19. *Adv Radiat Oncol* epub: ahead of print, 2020. PM32292839/PMC7118610
229. Zumsteg ZS, **Spratt DE**, Daskivich TJ, Tighiouart M, Luu M, Rodgers JP, Sandler HM: Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial. *JAMA Netw Open* 3(9): e2015083, 2020. PM32902647/PMC7489808
230. Dess RT, **Spratt DE**: Why the UK Should Consider Gene Expression Testing in Prostate Cancer. *Clin Oncol (R Coll Radiol)* 32(3): 149-155, 2020. PM31839379
231. Dee EC, Muralidhar V, Arega MA, Kishan AU, **Spratt DE**, Dess RT, King MT, Sha ST, Santos PMG, Butler SS, Sanford NN, Nguyen PL, Mahal BA: Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys*: 2020. PM33276019
232. Zheng Y, Gao W, **Spratt DE**, Sun Y, Xing L: Management of gastrointestinal perforation related to radiation. *Int J Clin Oncol* 25(6): 1010-1015, 2020. PM32303874
233. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, **Spratt DE**, Feng F: Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. *JCO Precis Oncol* 4: 1228-1238, 2020. PM35050780
234. Royce TJ, Switchenko JM, Zhang C, **Spratt DE**, Chen RC, Jani AB, Patel SA: Low Utilization of Androgen Deprivation Therapy Among Men Receiving Stereotactic Body Radiotherapy for Localized Prostate Cancer in the United States. *Eur Urol Oncol* epub: ahead of print, 2020. PM32624420
235. Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O'Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, **Spratt DE**: The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. *Eur Urol* epub: ahead of print, 2020. PM32893062/PMC7471715
236. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, **Spratt DE**: A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. *Eur Urol*: 2020. PM33293078
237. Mannan R, Wang X, Bawa PS, **Spratt DE**, Wilson A, Jentzen J, Chinnaiyan AM, Reichert ZR, Mehra R: Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. *Med Oncol* 37(3): 16, 2020. PM32030484
238. Milgrom SA, **Spratt DE**: Association or Causality: Does Whole Brain Proton Radiotherapy Not Impact IQ? (Letter to the Editor). *J Clin Oncol* epub: ahead of print, 2020. PM32374642
239. Goldberg H, **Spratt DE**, Chandrasekar T, Klaassen Z, Wallis CJD, Santiago-Jimenez M, Fishbane N, Davicioni E, Noorani R, Ahmad AE, Herrera Cáceres JO, Alibhai S, Berlin A, Fleshner NE: Clinicalgenomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. *Eur Urol Focus* epub: ahead of print, 2020. PM32156491
240. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, 240. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, **Spratt DE**, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU: Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. *Radiother Oncol* 154: 207-213, 2020. PM33035622
241. Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, **Spratt DE**, Den RB, Rebbeck TR, Feng F: Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. *Eur Urol* epub: ahead of print, 2020. PM33303244

242. Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA, Schaeffer EM, **Spratt D**, Yamoah K, Nguyen PL, Rebbeck TR: Racial Differences in Genomic Profiling of Prostate Cancer. *N Engl J Med* 383(11): 1083-1085, 2020. PM32905685
243. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, **Spratt DE**, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU: A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). *Eur Urol*: 2020. PM33309278
244. Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, **Spratt DE**, Wahl D, Eisner J, Pierce LJ, Speers C: Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. *Front Endocrinol (Lausanne)* 11: 35, 2020. PM32117061/PMC7027396
245. Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, **Spratt DE**, Lehrer E, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU: Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients. *Radiother Oncol* epub: ahead of print, 2020. PM32663537
246. **Spratt DE**, Tward JD: Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32928598
247. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efsthathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M 3rd, **Spratt DE**: Addition of Androgen Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. *J Clin Oncol* epub: JCO1903217, 2020. PM32396488
248. Couñago F, López-Campos F, Díaz-Gavela AA, Almagro E, Fenández-Pascual E, Henríquez I, Lozano R, Linares Espinós E, Gómez-Iturriaga A, de Velasco G, Quintana Franco LM, Rodríguez-Melcón I, López-Torrecilla J, **Spratt DE**, Guerrero LL, Martínez-Salamanca JI, Del Cerro E: Clinical Applications of Molecular Biomarkers in Prostate Cancer. *Cancers (Basel)* 12(6): ahead of print, 2020. PM32545454 /PMC7352850
249. Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, **Spratt DE**, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR: Expression of the of the androgen receptor governs radiation resistance in a subset of glioblastomas vulnerable to anti-androgen therapy. *Mol Cancer Ther* epub: ahead of print, 2020. PM32796101
250. Taylor AS, McKenney JK, Osunkoya AO, Chan MP, Al-Ahmadie HA, **Spratt DE**, Fullen DR, Chinnaiyan AM, Brown NA, Mehra R: PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. *Mod Pathol* epub: ahead of print, 2020. PM31932679
251. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, **Spratt DE**, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU: Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32544574
252. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillissen S, Lorient Y, Mottet N, Parulekar W, Sandler H, **Spratt DE**, Sydes MR, Tombal B, Williams S, Sweeney CJ, ICECaP Working Group.: Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. *J Clin Oncol* epub: JCO1903114, 2020. PM32552276
253. Roy S, Grimes S, Eapen L, **Spratt DE**, Malone J, Craig J, Morgan SC, Malone S: Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32565318

254. Razavian N, Laucis A, Sun Y, **Spratt DE**, Owen D, Schonewolf C, Uppal S, Maturen KE, Jolly S: Radiation-Induced Insufficiency Fractures after Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32442476
255. Mannan R, Taylor AS, **Spratt DE**, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R: TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of longstanding prostatic adenocarcinoma. *Pathol Res Pract* 216(1): 152663, 2020. PM31630874
256. Faisal FA, Murali S, Kaur H, Vidotto T, Guedes LB, Correia Salles D, Kothari V, Tosoian JJ, Han S, Hovelson DH, Hu K, **Spratt DE**, Baras AS, Tomlins SA, Schaeffer EM, Lotan TL: CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. *Clin Cancer Res* epub: ahead of print, 2020. PM31969336
257. Jairath NK, Farha MW, Srinivasan S, Jairath R, Green MD, Dess RT, Jackson WC, Weiner AB, Schaeffer EM, Zhao SG, Feng FY, El Naqa I, **Spratt DE**: Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. *J Clin Med* 9(6): ahead of print, 2020. PM32599760
258. Michmerhuizen AR, **Spratt DE**, Pierce LJ, Speers CW: Are we there yet? Understanding androgen receptor signaling in breast cancer. *NPJ Breast Cancer* 6: 47, 2020. PM33062889/PMC7519666
259. Hall WA, Paulson E, Davis BJ, **Spratt DE**, Morgan TM, Dearnaley D, Tree AC, Efsthathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen P, Hope TA, Feng F, Sandler HM, Lawton CA: NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32861817
260. Zaorsky NG, **Spratt DE**, Kishan AU, Culp SH, Showalter TN: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options. *Front Oncol* 10: 1616, 2020. PM32984028 /PMC7481351
261. Hartman HE, Sun Y, Devasia TP, Chase EC, Jairath NK, Dess RT, Jackson WC, Morris E, Li P, Hochstedler KA, Abbott MR, Kidwell KM, Walter V, Wang M, Wang X, Zaorsky NG, Schipper MJ, **Spratt DE**: Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. *JAMA Oncol* epub: E1-E9, 2020. PM33119036/PMC7596687
262. Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, **Spratt DE**: Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. *Adv Radiat Oncol* 5(Suppl 1): 26-32, 2020. PM33145460 /PMC7598436
263. Jackson WC, Hartman HE, Dess RT, **Spratt DE**: Reply to L. C. Mendez et al and M. A. Kollmeier et al (Invited Commentary Reply). *J Clin Oncol* epub: JCO2002422, 2020. PM32997578
264. Beeler WH, Speth KA, Broderick MT, Jairath NK, Ballouz D, Gharzai LA, Jackson WC, Kim MM, Owen D, Szerlip NJ, Paradis KC, **Spratt DE**: Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. *Neurosurgery* 86(2): e164-e172, 2020. PM31541240
265. Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, **Spratt DE**, Davicioni E, Lotan Y, Lin DW: Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. *Pract Radiat Oncol* 10(2): e82-e90, 2020. PM31761540
266. Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, O'Day S, Morikawa A, **Spratt DE**, Junck L, Mammoser A, Hayman JA, Lawrence TS, Tsien CI, Aiken R, Goyal S, Abrouk N, Trimble M, Cao Y, Lao CD: BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2020. PM32169409
267. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, 267. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efsthathiou JA, Feng FY, Shipley WU, **Spratt DE**: Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. *JAMA Oncol* 6(5): 1-9, 2020. PM32215583/PMC7189892
268. Tosoian JJ, Birer SR, Karnes JR, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, **Spratt DE**:

- Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22gene genomic classifier. *Prostate Cancer Prostatic Dis* epub: ahead of print, 2020. PM32231245
269. Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, **Spratt DE**, Feng FY, Nguyen PL: Genomic and clinical characterization of stromal infiltration markers in prostate cancer. *Cancer* 126(7): 1407-12, 2020. PM31905251
270. White JM, Kuda-Wedagedara AN, Wicker MN, **Spratt DE**, Schopperle WM, Heath E, Viola NT: Detecting TRA-1-60 in cancer via a novel Zr-89 labeled immunoPET imaging agent. *Mol Pharm* 17(4): 1139-47, 2020. PM32069422/PMC7249247
271. Weiner AB, Vo AX, Desai AS, Hu JC, **Spratt DE**, Schaeffer EM: Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. *Cancer* epub: ahead of print, 2020. PM32343403
272. Abdulfatah E, Kennedy JM, Hafez K, Davenport MS, Xiao H, Weizer AZ, Palapattu GS, Morgan TM, Mannan R, Wang XM, Dhanasekaran SM, Kaffenberger SD, **Spratt DE**, Kunju L, Wu A, Lew M, Udager AM, Chinnaiyan AM, Mehra R: Clinicopathological Characterization of Renal Cell Carcinoma in Young Adults: a contemporary update and review of literature. *Histopathology* 76(6): 875-87, 2020. PM31872452
273. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, **Spratt DE**, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z: Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. *Proc Natl Acad Sci U S A* epub: ahead of print, 2020. PM32424106
274. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, **Spratt DE**, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB: Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. *Eur Urol* epub: ahead of print, 2020. PM32461072
275. Marascio J¹, **Spratt DE**¹, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB: Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. *Prostate Cancer Prostatic Dis* 23(2): 29502, 2020. PM31719663/PMC7237345
276. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian J, Morgan TM, Mehra R, Salami S, Nguyen PL, Lawton CA, Schaeffer EM, **Spratt DE***, Feng F*: Development and Validation of A Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate JCO Precision Oncology accepted: ahead of print, 2020.
277. Zhao SG, Chen WS, Li H, Foye A, Zhang M,...**Spratt DE**, Morgan TM, Bose, R...Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY (69 total authors): DNA methylation landscapes in advanced prostate cancer *Nature Genetics* accepted: ahead of print, 2020.
278. Kishan AU, Nickols NG, **Spratt DE**: Prostate-specific Membrane Antigen Positron Emission Tomography guided Radiotherapy. *Eur Urol Focus* epub: E1-E4, 2020. PM33046413
279. Roy S, Grimes S, Morgan SC, **Spratt DE**, Eapen L, Mac Rae RM, Malone J, Craig J, Malone S: Impact of Treating Physician on Radiotherapy Related Severe Toxicities in Men with Prostate Cancer. *Pract Radiat Oncol* epub: E1-E29, 2020. PM33068792
280. Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, **Spratt DE**, Siddiqui J, Kunju LP, Botbyl R, Chopra Z, Pandian B, Eyrich NW, Longton G, Zheng Y, Palapattu GS, Wei JT, Niknafs YS, Chinnaiyan AM: Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach. *J Urol* epub: E1-E25, 2020. PM33080150
281. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris 281. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, **Spratt DE**: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific

Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol epub: E1-E9, 2020. PM33090219/PMC7582232

282. Gharzai LA, Jiang R, Wallington D, Jones G, Biring S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, **Spratt DE**: Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol 22(3): 402-410, 2021. PM33662287
283. Biswas T, **Spratt DE**: Dose Escalation for Oligometastatic Disease: Is More Better? Int J Radiat Oncol Biol Phys 110(3): 680-681, 2021. PM34089675
284. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, **Spratt DE**, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D: Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open 4(7): e2115312, 2021. PM34196715/PMC8251338
285. Nagar H, **Spratt DE**: Prostate SBRT Dose Escalation (9 Gy \times 5, 13.3 Gy \times 3, 24 Gy \times 1): Are We Making Progress? Int J Radiat Oncol Biol Phys 111(1): 110-112, 2021. PM34348105
286. Zaorsky NG, Calais J, Fanti S, Tilki D, Dorff T, **Spratt DE**, Kishan AU: Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol 18(11): 643-668, 2021. PM34363040
287. Shoag JE, Hill A, Jung JH, **Spratt D**: Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial. Eur Urol 80(5): 674-675, 2021. PM34518023
288. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M 3rd, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, **Spratt DE**, Kishan AU: Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open 4(12): e2139769, 2021. PM34964855/PMC8717118
289. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, **Spratt DE**, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU: Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open 4(12): e2138550, 2021. PM34902034/PMC8669522
290. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, **Spratt DE**, Teply BA, Tward J, Shead DA, Freedman-Cass DA: NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw 19(2): 134-143, 2021. PM33545689
291. Chowdhury-Paulino IM, Ericsson C, Vince R Jr, **Spratt DE**, George DJ, Mucci LA: Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis: 2021. PM34475523
292. Wallis CJD, Klaassen Z, Jackson WC, Dess RT, Reichert ZR, Sun Y, **Spratt DE**: Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open 4(5): e2110950, 2021. PM34028551
293. Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagarino UG, Liu Y, Davicioni E, **Spratt DE**, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, Greenberger MD, Bradley R, Watson JM, Beamer M, Stamatakis L, Carmen DJ, Awasthi S, Hwang J, Weil R, Merisaari H, Mohamed N, Deane LA, Chakravarty D, Yadav KK, Yamoah K, Nair SS, Tewari AK: Comparative analysis of 1152

AfricanAmerican and European-American men with prostate cancer identifies distinct genomic and immunological differences. *Commun Biol* 4(1): 670, 2021. PM34083737/PMC8175556

294. Dess RT, Jackson WC, **Spratt DE**: End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging? *J Clin Oncol* epub: JCO2100376, 2021. PM34086486
295. Weiner AB, Liu Y, McFarlane M, Bawa PS, Li EV, Zhao X, Li Z, Hammoud T, Hazime M, Karnes RJ, Davicioni E, Reichert ZR, Chinnaiyan AM, Lotan TL, **Spratt DE**, Schaeffer EM: A transcriptomic model for homologous recombination deficiency in prostate cancer. *Prostate Cancer Prostatic Dis*: 2021. PM34226663
296. Ploussard G, Fossati N, Wiegel T, D'Amico A, Hofman MS, Gillessen S, Mottet N, Joniau S, **Spratt DE**: Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. *Eur Urol Oncol* epub: ahead of print, 2021. PM33574012
297. Fredman ET, Guo G, **Spratt DE**: Importance of radiotherapy to the primary in metastatic hormone sensitive prostate cancer. *Prostate Cancer Prostatic Dis* epub: ahead of print, 2021. PM33833377
298. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan A, **Spratt DE**, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY: Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. *Eur Urol* epub: ahead of print, 2021. PM33840559
299. **Spratt DE**, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF: Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. *J Clin Oncol* 39(2): 136-144, 2021. PM33275486
300. Weiner AB, Vidotto T, Liu Y, Mendes AA, Salles DC, Faisal FA, Murali S, McFarlane M, Imada EL, Zhao X, Li Z, Davicioni E, Marchionni L, Chinnaiyan AM, Freedland SJ, **Spratt DE**, Wu JD, Lotan TL, Schaeffer EM: Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. *Nat Commun* 12(1): 935, 2021. PM33568675
301. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, **Spratt DE**, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU: Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. *Eur Urol* epub: ahead of print, 2021. PM33985797
302. Feng FY, Huang HC, **Spratt DE**, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efsthathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT: Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. *JAMA Oncol* epub: ahead of print, 2021. PM33570548
303. Li P, Taylor JMG, **Spratt DE**, Karnes RJ, Schipper MJ: Evaluation of predictive model performance of an existing model in the presence of missing data. *Stat Med* epub: ahead of print, 2021. PM33843085
304. Vince R Jr, **Spratt DE**: Drivers of racial disparities in prostate cancer trial enrollment. *Prostate Cancer Prostatic Dis*: 2021. PM34253848
305. Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, Palapattu GS, Vaishampayan UN, Alumkal JJ, **Spratt DE**, Udager AM, Mehra R: De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. *Med Oncol* 38(3): 26, 2021. PM33586037
306. Wang XM, Zhang Y, Mannan R, Skala SL, Rangaswamy R, Chinnaiyan A, Su F, Cao X, Zelenka-Wang S, McMurry L, Xiao H, **Spratt DE**, Sangoi AR, Shao L, Betz BL, Brown N, Tickoo SK, McKenney JK, Argani P, Gupta S, Reuter VE, Chinnaiyan AM, Dhanasekaran SM, Mehra R: TRIM63 is a sensitive and specific

- biomarker for MiT family aberration-associated renal cell carcinoma. *Mod Pathol* epub: ahead of print, 2021. PM33854184
307. Efsthathiou JA, Kamran SC, **Spratt DE**: Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming. *Int J Radiat Oncol Biol Phys* 110(4): 1098-1100, 2021. PM34171235
 308. Zaorsky NG, **Spratt DE**: Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all? *Int J Radiat Oncol Biol Phys* 111(4): 965-967, 2021. PM34655565
 309. Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, **Spratt DE**, Kishan AU: Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. *Prostate Cancer Prostatic Dis*: 2021. PM34400799
 310. Campbell SR, Tom MC, Agrawal S, Efsthathiou JA, Michalski JM, Abramowitz MC, Pollack A, **Spratt DE**, Hearn JWD, Stephans KL, Gao T, Li J, Tendulkar RD: Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. *Eur Urol Oncol* epub: ahead of print, 2021. PM34016556
 311. **Spratt DE**, Shore N, Sartor O, Rathkopf D, Olivier K: Treating the patient and not just the cancer: therapeutic burden in prostate cancer. *Prostate Cancer Prostatic Dis* epub: ahead of print, 2021. PM33603236
 312. Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, **Spratt DE**, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhota S, Campeau E, Yates JA, Xia Z, Alumkal JJ: BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. *Clin Cancer Res* epub: ahead of print, 2021. PM34145028
 313. Zaorsky NG, Garrett S, **Spratt DE**, Nguyen PL, Sciamanna C, Schmitz K: Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. *Int J Radiat Oncol Biol Phys*: 2021. PM34561128
 314. Vince RA Jr, Jiang R, Qi J, Tosoian JJ, Takele R, Feng FY, Linsell S, Johnson A, Shetty S, Hurley P, Miller DC, George A, Ghani K, Sun F, Seymore M, Dess RT, Jackson WC, Schipper M, **Spratt DE**, Morgan TM: Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. *Prostate Cancer Prostatic Dis*: 2021. PM34285350
 315. Zaorsky NG, Wang X, Garrett SM, Lehrer EJ, Lin C, DeGraff DJ, **Spratt DE**, Trifiletti DM, Kishan AU, Showalter TN, Park HS, Yang JT, Chinchilli VM, Wang M: Pan-cancer analysis of prognostic metastatic phenotypes. *Int J Cancer*: 2021. PM34287840
 316. Slevin F, Aitken K, Alongi F, Arcangeli S, Chadwick E, Chang AR, Cheung P, Crane C, Guckenberger M, Jerezek-Fossa BA, Kamran SC, Kinj R, Loi M, Mahadevan A, Massacesi M, Mendez LC, Muirhead R, Pasquier D, Pontoriero A, **Spratt DE**, Tsang YM, Zelefsky MJ, Lilley J, Dickinson P, Hawkins MA, Henry AM, Murray LJ: An international Delphi consensus for pelvic stereotactic ablative radiotherapy reirradiation. *Radiother Oncol* 164: 104-114, 2021. PM34560186
 317. Sapienza LG, Ning MS, Carvalho EF, **Spratt DE**, Calsavara VF, McLaughlin PW, Gomes MJL, Baiocchi G, Abu-Isa E: Efficacy and Incontinence Rates After Urethroplasty for Radiation-induced Urethral Stenosis: A Systematic Review and Meta-analysis. *Urology* Epub: ahead of print, 2021. PM33631205
 318. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, **Spratt DE**, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin A: Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. *J Natl Cancer Inst*: 2021. PM34291289
 319. Henriquez I, **Spratt DE**, Gómez-Iturriaga A, Abuchaibe O, Couñago F: Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. *World J Clin Oncol* 12(1): 6-12, 2021. PM33552935/PMC7829629
 320. McFarlane MR, Hochstedler KA, Laucis AM, Sun Y, Chowdhury A, Matuszak MM, Hayman J, Bergsma D, Boike T, Kestin L, Movsas B, Grills I, Dominello M, Dess RT, Schonewolf C, **Spratt DE**, Pierce L, Paximadis P, Jolly S, Schipper M: Predictors of Pneumonitis after Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. *Int J Radiat Oncol Biol Phys*: 2021. PM34314815
 321. Jaworski EM, Yin H, Griffith KA, Pandya R, Mancini BR, Jolly S, Boike TP, Moran JM, Dominello MM, Wilson M, Parker J, Burmeister J, Fraser C, Miller L, Baldwin K, Mietzel MA, Grubb M, Kendrick D, **Spratt DE**, Hayman JA, Michigan Radiation Oncology Quality Consortium.: Contemporary practice patterns for

- palliative radiotherapy of bone metastases: Impact of a quality improvement project on extended fractionation. *Pract Radiat Oncol* epub: ahead of print, 2021. PM34048938
322. Daskivich TJ, Luu M, Freedland SJ, Sandler H, **Spratt DE**, Zumsteg ZS: Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer. *J Urol*: 101097JU00000000000002256, 2021. PM34694160
 323. Vince RA Jr, Eyrich NW, Mahal BA, Stensland K, Schaeffer EM, **Spratt DE**: Reporting of Racial Health Disparities Research: Are We Making Progress? *J Clin Oncol*: JCO2101780, 2021. PM34694897
 324. Al Hussein Al Awamih B, **Spratt DE**, Shoag JE: MRI-Targeted Biopsy in Prostate Cancer Screening. *N Engl J Med* 385(22): 2109-2110, 2021. PM34818496
 325. Chang P, Wagner AA, Regan MM, Smith JA, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Partin AW, Wood DP, Crociani CM, Greenfield TK, Patil D, Hembroff LA, Davis K, Stork L, **Spratt DE**, Wei JT, Sanda MG: Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. *J Urol*: 101097JU00000000000002176, 2021. PM34433304
 326. Schumacher FR, Basourakos SP, Lewicki PJ, Vince R, **Spratt DE**, Barbieri CE, Shoag JE: Race and Genetic Alterations in Prostate Cancer. *JCO Precis Oncol* 5: 2021. PM34746633/PMC8563071
 327. Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, **Spratt DE**, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M: Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). *Cancer Genet* 258-259: 61-68, 2021. PM34551377
 328. Roy S, Grimes S, Morgan SC, Eapen L, Malone J, Craig J, **Spratt DE**, Malone S: Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2021. PM33524545
 329. Yee TJ, Saadeh YS, Strong MJ, Ward AL, Elswick CM, Srinivasan S, Park P, Oppenlander ME, **Spratt DE**, Jackson WC, Szerlip NJ: Survival, fusion, and hardware failure after surgery for spinal metastatic disease. *J Neurosurg Spine* epub: 1-8, 2021. PM33513569
 330. **Spratt DE**, Malone S, Roy S, Sun Y, Lawton C: Reply to S. Sundar et al and S. Höcht et al. *J Clin Oncol* epub: JCO2100411, 2021. PM33914593
 331. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, **Spratt DE**, Johnson TD, Scott PJH, Pierr M: A comprehensive assessment of ⁶⁸Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. *J Nucl Med*: 2021. PM34326126
 332. Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, **Spratt DE**: An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 113(2): 278-289, 2022. PM34923058
 333. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efsthathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, **Spratt DE**, MARCAP Consortium group.: Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. *Lancet Oncol* 23(2): 304-316, 2022. PM35051385
 334. Jia AY, **Spratt DE**: Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative. *Int J Radiat Oncol Biol Phys* 113(2): 316-319, 2022. PM35569476
 335. Alshalalfa M, Seldon C, Franco I, Vince R, Carmona R, Punnen S, Kaochar S, Dess R, Kishan A, **Spratt DE**, Sharma J, Dal Pra A, Pollack A, Abramowitz MC, Mahal BA: Clinicogenomic characterization of prostate cancer liver metastases. *Prostate Cancer Prostatic Dis* 25(2): 366-369, 2022. PM35022600
 336. Chase EC, Bryant AK, Sun Y, Jackson WC, **Spratt DE**, Dess RT, Schipper MJ: Development and validation of a life expectancy calculator for US patients with prostate cancer. *BJU Int* 130(4): 496-506, 2022. PM35373440/PMC9474626
 337. Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, **Spratt DE**, Ost P, Feng FY, Tran PT: Genomic biomarkers to guide

precision radiotherapy in prostate cancer. *Prostate* 82 Suppl 1: S73-S85, 2022. PM35657158 /PMC9202472

338. Basourakos SP, Gulati R, Vince RA Jr, **Spratt DE**, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. *NEJM Evid* 1(6): 2022. PM35721307/PMC9202998
339. Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, **Spratt DE**, MARCAP Consortium.: Highdose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. *Eur Urol* 82(1): 106-114, 2022. PM35469702
340. Labe SA, Wang X, Lehrer EJ, Kishan AU, **Spratt DE**, Lin C, Morgans AK, Ponsky L, Garcia JA, Garrett S, Wang M, Zaorsky NG: Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. *Clin Genitourin Cancer* 20(4): 371-380, 2022. PM35383004/PMC9329179
341. Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Comp erat E, Roubaud G, Massard C, Merseburger AS, Leapman MS, **Spratt DE**, Saad F, Joniau S, D'Amico AV, Briganti A, Shariat SF, Ploussard G, European Association of Urology Young Academic Urologists Prostate Cancer Working Party.: Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol* 82(1): 82-96, 2022. PM35465985
342. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, **Spratt DE**, Romero T: Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. *JAMA Oncol* 8(3): e216871, 2022. PM35050303/PMC8778608
343. Jia AY, Kashani R, Zaorsky NG, Baumann BC, Michalski J, Zoberi JE, Kiess AP, **Spratt DE**: Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review. *Pract Radiat Oncol* 12(4): 294-299, 2022. PM35717043
344. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, **Spratt DE**, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, T rkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A: Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol* 82(1): 115-141, 2022. PM35450732
345. Arenas-Gallo C, Owiredu J, Weinstein I, Lewicki P, Basourakos SP, Vince R Jr, Al Hussein Al Awamih B, Schumacher FR, **Spratt DE**, Barbieri CE, Shoag JE: Race and prostate cancer: genomic landscape. *Nat Rev Urol* 19(9): 547-561, 2022. PM35945369
346. Laucis AMB, Hochstedler KA, Schipper MJ, Paximadis PA, Boike TP, Bergsma DP, Movsas B, Kretzler A, **Spratt DE**, Dess RT, Mietzel MA, Dominello MM, Matuszak MM, Jagsi R, Hayman JA, Pierce LJ, Jolly S: Racial Differences in Treatments and Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Thoracic Radiation Therapy. *JCO Oncol Pract* 18(6): e1034-e1044, 2022. PM35167337
347. Kishan AU, **Spratt DE**: Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. *Eur Urol*. 2022;82:106-114. *Eur Urol* 82(3): e82e83, 2022. PM35688665

348. Gomez-Iturriaga A, Keyes M, Martin J, **Spratt DE**: Should brachytherapy be added to external beam radiotherapy for prostate cancer? *Lancet Oncol* 23(1): 23-25, 2022. PM34973217
349. Wittmann D, Mehta A, Bober SL, Zhu Z, Daignault-Newton S, Dunn RL, Braun TM, Carter C, Duby A, Northouse LL, Koontz BF, Glodé LM, Brandon J, Bangs R, McPhail J, McPhail S, Arab L, Paich K, Skolarus TA, An LC, Nelson CJ, Saigal CS, Chen RC, Mulhall JP, Hawley ST, Hearn JWD, **Spratt DE**, Pollack CE: TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results. *Cancer* 128(7): 1513-1522, 2022. PM34985771
350. Taylor AS, Newell B, Chinnaiyan AM, Hafez KS, Weizer AZ, **Spratt DE**, Cameron AP, Al-Ahmadie HA, Gupta S, Montgomery JS, Betz BL, Brown N, Mehra R: *TERT* Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. *Eur Urol Open Sci* 35: 74-78, 2022. PM35024637/PMC8738896
351. Baboudjian M, Breda A, Rajwa P, Gallioli A, Gondran-Tellier B, Sanguedolce F, Verri P, Diana P, Territo A, Bastide C, **Spratt DE**, Loeb S, Tosoian JJ, Leapman MS, Palou J, Ploussard G: Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression. *Eur Urol Oncol*: 2022. PM35934625
352. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M 3rd, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, **Spratt DE**, Kishan AU, Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators.: Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). *Eur Urol*: 2022. PM35934601
353. Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J, Kishan AU, Mukherjee D, **Spratt DE**, Saad F, Malone S: Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. *Prostate Cancer Prostatic Dis*: 2022. PM35790787
354. Dadhania V, Gonzalez D, Yousif M, Cheng J, Morgan TM, **Spratt DE**, Reichert ZR, Mannan R, Wang X, Chinnaiyan A, Cao X, Dhanasekaran SM, Chinnaiyan AM, Pantanowitz L, Mehra R: Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. *BMC Cancer* 22(1): 494, 2022. PM35513774/PMC9069768
355. Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, Klaassen Z, Malone S, **Spratt DE**, Wallis CJD, Morgan SC: Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. *Eur Urol Oncol*: 2022. PM35811293
356. Vince RA Jr, Sun Y, Mahal B, Ginsburg K, George A, Cher M, Lane B, Sarle R, Morgan TM, **Spratt DE**: The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide. *Eur Urol*: 2022. PM35688664
357. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium., Sandler HM, Tran PT, **Spratt DE**, Pugh S, Feng FY, Mohamad O: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. *NPJ Digit Med* 5(1): 71, 2022. PM35676445/PMC9177850
358. Okoth LA, Harris AC, Singhal U, Cher ML, **Spratt DE**, Morgan TM: Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers. *Eur Urol Focus*: 2022. PM35963777
359. Nguyen AT, Luu M, Nguyen VP, Lu DJ, Shiao SL, Kamrava M, Atkins KM, Mita AC, Scher KS, **Spratt DE**, Faries MB, Daskivich TJ, Lin DC, Chen MM, Clair JM, Sandler HM, Ho AS, Zumsteg ZS: Quantitative Nodal Burden and Mortality Across Solid Cancers. *J Natl Cancer Inst* 114(7): 1003-1011, 2022. PM35311991/PMC9275768
360. Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, **Spratt DE**, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG: Local Treatment of the Primary Tumor for Patients with Metastatic Cancer (PRIME-TX): A Meta-analysis. *Int J Radiat Oncol Biol Phys*: 2022. PM35840112
361. Roy S, Morgan SC, Wallis CJD, Sun Y, **Spratt DE**, Malone J, Grimes S, Mukherjee D, Kishan AU, Saad F, Malone S: Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study. *Prostate Cancer Prostatic Dis*: 2022. PM36097167

362. Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, Gu S, Tang Q, Zhang Y, Syamala S, Seo JH, Bell C, O'Connor E, Liu Y, Schaeffer EM, Jeffrey Karnes R, Weinmann S, Davicioni E, Morrissey C, Cejas P, Ellis L, Loda M, Wucherpennig KW, Pomerantz MM, **Spratt DE**, Corey E, Freedman ML, Shirley Liu X, Brown M, Long HW, Labbé DP: MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. *Nat Commun* 13 (1): 2559, 2022. PM35562350/PMC9106722
363. Wilkie JR, Hochstedler KA, Schipper MJ, Matuszak MM, Paximadis P, Dominello MM, Grills I, Hayman JA, Dess R, Dragovic AF, Jagsi R, Pierce LJ, **Spratt DE**, Bergsma D, Boike TP, Movsas B, Jolly S, Michigan Radiation Oncology Quality Consortium.: Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. *Int J Radiat Oncol Biol Phys* 112(4): 942-950, 2022. PM34838865
364. Roy S, **Spratt DE**, Morgan SC, Zhou M, D'Souza LA, Drogos F, Malone J, Grimes S, Gualano C, MacRae R, Mukherjee D, Malone S: Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial. *Int J Radiat Oncol Biol Phys* 112(4): 880-889, 2022. PM34788698
365. Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efsthathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, **Spratt DE**: Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. *J Clin Oncol* 40(27): 3172-3179, 2022. PM35737923/PMC9514834
366. Hammer L, Jiang R, Hearn J, Lashbrook J, Mitchell A, Daignault-Newton S, Dess RT, Jackson WC, Reichert Z, Alumkal JJ, Kaffenberger S, George A, Montgomery J, Salami SS, Morgan TM, Miller D, Wittman D, Hollenbeck B, Mehra R, Davenport MS, Sun Y, Schipper M, Palapattu G, **Spratt DE**: A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. *Int J Radiat Oncol Biol Phys*: 2022. PM35878714
367. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, **Spratt DE**, Xiang M, Kishan AU: External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. *Int J Radiat Oncol Biol Phys*: 2022. PM36179990
368. McClelland S 3rd, Harris EE, **Spratt DE**, Cheatham C, Sun Y, Oliver AL, Jaboin JJ, Jagsi R, Petereit DG: Navigator-assisted hypofractionation (NAVAH) to address radiation therapy access disparities facing African-Americans with breast cancer. *Rep Pract Oncol Radiother* 27(3): 583-588, 2022. PM36186700 /PMC9518767
369. Hall WA, Shoag J, **Spratt DE**: Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study. *Eur Urol*: 2022. PM36184380
370. Shen X, **Spratt DE**, Dusetzina SB, Chen RC: Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures. *Int J Radiat Oncol Biol Phys* epub: ahead of print, 2022. PM35918053
371. Okoth LA, Harris AC, Singhal U, Cher ML, **Spratt DE**, Morgan TM. Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers. *Eur Urol Focus*. 2022 Jul;8(4):897-900. doi: 10.1016/j.euf.2022.08.001. Epub 2022 Aug 10. PMID: 35963777.
372. Mannan R, Wang X, Bawa PS, Zhang Y, Skala SL, Chinnaiyan AK, Dagar A, Wang L, Zelenka-Wang SB, McMurry LM, Daniel N, Cao X, Sangoi AR, Gupta S, Vaishampayan UN, Hafez KS, Morgan TM, **Spratt DE**, Tretiakova MS, Argani P, Chinnaiyan AM, Dhanasekaran SM, Mehra R. Characterization of Intercalated Cell Markers KIT and *LINC01187* in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms. *Int J Surg Pathol*. 2022 Oct 16:10668969221125793. doi: 10.1177/10668969221125793. Epub ahead of print. PMID: 36250542.
373. Cantley RL, Wang X, Reichert ZR, Chinnaiyan AM, Mannan R, Cao X, **Spratt DE**, Vaishampayan UN, Alumkal JJ, Morgan TM, Palapattu G, Davenport MS, Pantanowitz L, Mehra R. Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates. *Cancer Cytopathol*. 2023 Feb;131(2):117-135. doi: 10.1002/cncy.22652. Epub 2022 Oct 20. PMID: 36264673; PMCID: PMC10092797.

374. Ma TM, Sun Y, Malone S, Roach M 3rd, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, **Spratt DE**, Kishan AU; Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. *J Clin Oncol*. 2023 Feb 1;41(4):881-892. doi: 10.1200/JCO.22.00970. Epub 2022 Oct 21. PMID: 36269935; PMCID: PMC9902004.
375. **Spratt DE**. The use of AI to identify predictive, pathology-based biomarkers in men with prostate cancer. *Clin Adv Hematol Oncol*. 2022 Nov;20(11):659-661. PMID: 36331403.
376. Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, **Spratt DE**, Feng F, Wang H, Beer TM, Antonarakis ES. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. *J Clin Oncol*. 2023 Feb 20;41(6):1307-1317. doi: 10.1200/JCO.22.01662. Epub 2022 Nov 11. PMID: 36367998; PMCID: PMC9940936.
377. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khaulil RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, **Spratt DE**, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. *Eur Urol*. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6. PMID: 36494221.
378. Jia AY, **Spratt DE**. Radiotherapy in patients with node-positive prostate cancer after radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2022 Dec 16. doi: 10.1038/s41391-022-00631-5. Epub ahead of print. PMID: 36526683.
379. Nguyen PL, Huang HR, **Spratt DE**, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. *Int J Radiat Oncol Biol Phys*. 2022 Dec 31;S0360-3016(22)03688-4. doi: 10.1016/j.ijrobp.2022.12.035. Epub ahead of print. PMID: 36596347.
380. Vince RA Jr, Jiang R, Bank M, Quarles J, Patel M, Sun Y, Hartman H, Zaorsky NG, Jia A, Shoag J, Dess RT, Mahal BA, Stensland K, Eyrich NW, Seymore M, Takele R, Morgan TM, Schipper M, **Spratt DE**. Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023 Jan 3;6(1):e2250416. doi: 10.1001/jamanetworkopen.2022.50416. Erratum in: *JAMA Netw Open*. 2023 Feb 1;6(2):e231256. PMID: 36630135; PMCID: PMC9857531.
381. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, Tran PT, **Spratt DE**, Pugh S, Feng FY, Mohamad O. Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. *NPJ Digit Med*. 2023 Feb 22;6(1):27. doi: 10.1038/s41746-023-00769-z. Erratum for: *NPJ Digit Med*. 2022 Jun 8;5(1):71. PMID: 36813827; PMCID: PMC9947124.
382. **Spratt DE**. In Reply to Onal et al. *Int J Radiat Oncol Biol Phys*. 2023 Jan 1;115(1):254-255. doi: 10.1016/j.ijrobp.2022.10.006. PMID: 36526390.

383. Martin T, Sun Y, **Spratt DE**, Kishan AU. Reply to A. Abner et al. *J Clin Oncol*. 2023 Mar 1;JCO2202928. doi: 10.1200/JCO.22.02928. Epub ahead of print. PMID: 36857621.
384. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, **Spratt DE**, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. *Eur Urol Oncol*. 2023 Apr;6(2):224-227. doi: 10.1016/j.euo.2023.02.009. Epub 2023 Mar 2. PMID: 36870853.
385. Roy S, Sun Y, Morgan SC, Wallis CJD, King K, Zhou YM, D'souza LA, Azem O, Cueto-Marquez AE, Camden NB, **Spratt DE**, Kishan AU, Saad F, Malone S. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. *Eur Urol*. 2023 Mar 7:S0302-2838(23)02626-X. doi: 10.1016/j.eururo.2023.02.017. Epub ahead of print. PMID: 36894488.
386. Ma TM, Feng FY, Rosenthal SA, Rettig MB, Raldow AC, **Spratt DE**, Xiang M, Kishan AU. Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era. *Prostate Cancer Prostatic Dis*. 2023 Mar 25. doi: 10.1038/s41391-023-00663-5. Epub ahead of print. PMID: 36966268.
387. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, **Spratt DE**, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. *Eur J Cancer*. 2023 Mar 3;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub ahead of print. PMID: 37003085.
388. Chinniah S, Chiam M, Mani K, Liang M, Trifiletti DM, **Spratt DE**, Prasad VK, Wang M, Tchelebi LT, Zaorsky NG. Unknown Causes of Death in Cancer Patients. *Am J Clin Oncol*. 2023 Apr 11. doi: 10.1097/COC.0000000000001003. Epub ahead of print. PMID: 37038261.
389. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, **Spratt DE**, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. *Cancer*. 2023 Apr 14. doi: 10.1002/cncr.34790. Epub ahead of print. PMID: 37060201.
390. Roy S, Wallis CJD, Morgan SC, Kishan AU, Le ATT, Malone J, Sun Y, **Spratt DE**, Saad F, Malone S. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer. *Prostate*. 2023 Apr 18. doi: 10.1002/pros.24512. Epub ahead of print. PMID: 37071764.

Non-Peer-Reviewed Journals and Publications

Spratt D: Invited Editorial *J Urol* 197(4): 1075, 2017. PMID: 28093247

Spratt DE: In Reply to Wilkins et al. (Invited Commentary Reply) *Int J Radiat Oncol Biol Phys* 102(5): 1597-1598, 2018. PMID: 31014791

Spratt DE: Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer. (Invited Editorial). *Urology- Practice Update* <https://www.practiceupdate.com>: online, 2018.

Spratt DE: Not all patients who fail salvage radiotherapy are destined for poor outcomes. (Invited Editorial). *Urology- Practice Update* www.practiceupdate.com: null, 2018.

Spratt DE: What Are We Even Looking At? (Invited Commentary). *Int J Radiat Oncol Biol Phys* 104(2): 264-265, 2019. PMID: 31047625

Spratt DE: Prostate Cancer Transcriptomic Subtypes. (Invited Review). *Adv Exp Med Biol* 1210: 111-120, 2019. PMID: 31900907

Spratt DE: The Rapidly Evolving Treatment Landscape of Prostate Cancer-The Convergence of Treatment Paradigms of Localized and Metastatic Diseases. (Invited Commentary). *Cancer J* 26(1): 1, 2020. PM31977378

Spratt DE: Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion. (Invited Commentary) *Int J Radiat Oncol Biol Phys* 108(2): 338-339, 2020. PM32890502

Spratt DE: Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. (Invited Editorial). *J Urol* epub: 101097JU77402, 2020. PM32329648

Spratt DE, Dess RT: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer (Invited commentary) *PracticeUpdate* website *PracticeUpdate*: online, 2021.

Book Chapters

1. **Spratt DE,** Cabanillas R, Lee NY: The Paranasal Sinuses. Target Volume Delineation and Field Setup. Springer Berlin Heidelberg, Lee NY, Lu Jiade Springer Berlin Heidelberg, 2013. 45-48
2. **Spratt DE,** Reyngold M, Yamada Y: Stereotactic Radiotherapy. Pocket Oncology, Drilon AE, Postow MA, Krug LM Wolters Kluwer, 2014. 20-22
3. **Spratt DE,** Lee NY: Carcinoma of the Paranasal Sinuses. Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy, Lee NY, Riaz N, Lu J Springer International Publishing, 2015. 8389
4. Jackson W, **Spratt DE,** Morgan TM: Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. *Prostate Cancer*, Sam S Chang and Michael S Cookson Springer Nature, 2018.
5. Szerlip N, Beeler W, **Spratt DE:** Malignant Spinal Cord Compression. Principles and Practice of Oncology (Cancer: Principles & Practice (DeVita), Vincent T. DeVita Jr. Jr. MD and Theodore S. Lawrence PhD MD wolters kluwer, 2018.
6. Trifiletti DM, Zaorsky NG, **Spratt DE:** Spine and bone metastases. *Absolute Clinical Radiation Oncology Review*, Trifiletti DM, Zaorsky NG Springer, 2018.
7. Moraes FY, Chen X, Yan M, **Spratt DE,** Redmond K, Jackson WC, Yamada YJ: Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases: Defining Dose and Dose Constraints. *Neurosurgery Clinics of North America, Spinal Oncology*, Eds: Lonser RR, Resnick DK Elsevier, 2020. 167-89
8. Roy S, **Spratt DE:** Radiotherapy for Advanced Prostate Cancer. *Urologic Oncology: Multidisciplinary Care for Patients*, Morgans A Springer, 2021.
9. Dess RT, Jackson WC, **Spratt DE:** The Management of Prostate Cancer. *Radiation Therapy for Genitourinary Malignancies. A Practical and Technial Guide*, Editors: Solanki AA, Chen RC Springer, 2021. 1, 3-24
10. Dess RT, **Spratt DE:** Gene Expression Biomarkers in Prostate Cancer for Men Receiving Radiotherapy. *Prostate Cancer Controversies IV*, Lopez IH, **Spratt DE,** Iturriaga AG Emiral, 2021.
11. **Spratt DE:** Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Current State of Systemic Treatment Options. *Prostate Cancer Controversies IV*, Lopez IH, Spratt DE, Iturriaga AG Emiral, 2021.
12. Dess RT, **Spratt DE:** Role of local radiotherapy mHSPC. Who benefit from it?. *Prostate Cancer Controversies IV*, Lopez IH, Spratt DE, Iturriaga AG Emiral, 2021.

Books

1. Lopez IH, **Spratt DE,** Iturriaga AG: *Prostate Cancer Controversies IV*, Emiral, Spain, 2021.

Other Media

Editorial comment

1. **Spratt DE:** ASCO Oncology Fellow Advisor, Commentary on radiation oncology training in the United States., American Society of Clinical Oncology, 2012.
2. Knoll MA, George TJ, Eng C, **Spratt DE,** Robinson C: Harnessing the Power of Twitter for Clinical Trial Enrollment and Success., Commentary on the utility of social media to improve clinical trial enrollment. <https://www.ascopost.com/issues/may-10-2019/harnessing-the-power-of-twitter-for-clinical-trial-enrollment-and-success/>., ASCO Post, 2019.

3. **Spratt DE**, Mitin T: The Future of Prostate Radiation Therapy in the Era of Bundled Payment: Less is more?, <https://www.astro.org/Blog/December-2019/The-Future-of-Prostate-Radiation-Therapy-in-the-Er.>, ASTRO Blog Online, 2019.

Patient educational material

1. **Spratt DE**, Miyahira A, Cheng H, Loeb S, Cooperberg M, Morgans A, Burnett A, Sharifi N, Aronson W, Baccala A, SHore N, Armstrong A, Faiena I, Sweeney C, Soule H, Holden S, Simons J, Campbell R, DiBiase J: Prostate Cancer Patient Guide, The most comprehensive patient guide to prostate cancer. First released in 2017, updated for print in January 2019, and most recently updated in pdf in May 2020 by the Prostate Cancer Foundation (PCF). The Prostate Cancer Foundation is the world's leading philanthropic organization for prostate cancer research, Prostate Cancer Foundation, 2020.

Web sites

1. Hartman H, Schipper M, **Spratt DE**: OncCOVID Resource: Intersection of Oncology and Coronavirus (COVID-19): Integrated Survival Estimates from Immediate versus Delayed Cancer Treatment, The first integrating web-based model that estimates the overall survival from delaying cancer treatment during the Covid-19 global pandemic (<http://onccovid.med.umich.edu/>), 2020.

Abstracts

1. Jones L, **Spratt DE**, Yang JJ: Structural Biology of a Novel Calcium Binding Proteins, 14th Suddath Symposium of Signal Molecule Dynamics in Biology, Georgia Institute of Technology, Atlanta, GA, 2006.
2. Rajaram, R, **Spratt DE**, Mericle, R: The Use of Dexamethasone in Non-Traumatic Subarachnoid Hemorrhage Patients, American Association of Neurological Surgeons, San Diego, CA, 2008.
3. **Spratt DE**, Salvetti DJ, Yao T, Simon S, Mericle R: Dexamethasone after subarachnoid hemorrhage: Effect on CSF biomarkers and angiographic cerebral vasospasm in a rabbit model, Emphasis Research Forum, Vanderbilt University, Nashville, TN, 2008.
4. **Spratt DE**, T, Simon, S Mericle, R, Ayad, M: Dexamethasone after Subarachnoid Hemorrhage in a Rabbit Model, Southern Neurological Society Meeting, San Juan Puerto Rico, 2008.
5. **Spratt DE**, Phillips JG, Diaz R, Crass J, Kirby W, Stinson S, Cmelak AJ: Comparison of IMRT With Planar RapidArc In Diffuse Cerebral Meningiomas, ASTRO's 51st Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 2009.
6. Passarella, RJ, **Spratt DE**, Zhou L, Wu HW, Hallahan DE, Diaz R: Glucose-regulated protein (GRP78) is induced by ionizing radiation in tumor samples, ASTRO's 51st Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 2009.
7. Philips JG, Passarella RJ, Van Der Ende A, **Spratt DE**, Hongmei W, Hallahan DE, Diaz R: A Novel Targeting Receptor for Radiation Assisted Drug Delivery, ASTRO's Translational Advances in Radiation Oncology and Cancer Imaging, St Louis, MO, Int J Radiat Oncol Biol Phys, 2009.
8. **Spratt DE**, Passarella RJ, Zhou Li, Van Der Ende A, Hongmei W, Hallahan DE, Diaz R: Targeting Radiation Induced Tumor Receptors, ASTRO's Translational Advances in Radiation Oncology and Cancer Imaging, St Louis, MO, 2009.
9. Phillips, JG, Passarella, RJ, **Spratt DE**, Van der Ende, A, Zhou L, Wu HW, Hallahan DE, Harth, E, Diaz R: A novel targeting ligand for X-ray guided drug delivery, American Society for Radiation Oncology 51st Annual Meeting, Chicago, IL, 2009.
10. **Spratt DE**, Diaz R, McElmurray J, Duggan D, Delbeke D, Lu B: Impact of 18F-FDG PET/CT Imaging on Radiation Treatment Planning of Patients with Non Small Cell Lung Cancer (NSCLC), RSNA 95th Scientific Assembly and Annual Meeting, Chicago, IL, 2009.
11. **Spratt DE**, Passarella RJ, Zhou Li, Van Der Ende A, Hongmei W, Hallahan DE, Diaz R: GRP78 Induction By Radiation and its Role in Targeted Chemotherapy, Mechanics of Malignancy, Tumor Angiogenesis, and Metastasis, Vanderbilt Ingram Cancer Center, Nashville, TN, Int J Radiat Oncol Biol Phys, 2009.
12. **Spratt DE**, Diaz R, McElmurray J, Duggan D, Delbeke D, Lu B: Impact of 18F-FDG PET/CT Imaging on Radiation Treatment Planning of Patients with Non-Small Cell Lung Cancer (NSCLC). Mechanics of Malignancy, Tumor Angiogenesis, and Metastasis, Vanderbilt Ingram Cancer Center, Nashville, TN, 2009.
13. **Spratt DE**, Pei, X, Yamada, J, Kollmeier, MA, Cox, B, Zhang, Z, Zelefsky MJ: Long-Term Survival and Toxicity of Patients Treated with Ultra-High-Dose IMRT for Localized Prostate Cancer, ASTRO's 54th Annual Meeting, Boston, MA., Int J Radiat Oncol Biol Phys, 2012.
14. Cox BW, **Spratt DE**, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y: International Spine

Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery, American Radium Society, 94th Annual Meeting, Las Vegas, NV, 2012.

15. Zumsteg Z, **Spratt DE**, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ: Short-term Androgen-deprivation Therapy Improves Prostate Cancer-specific Mortality in Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External Beam Radiation Therapy, American Society for Radiation Oncology 54th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2012.
16. Vlacich GR, **Spratt DE**, Diaz R, Phillips JG, Crass J, Li C, Shyr Y, Cmelak AJ: Dose to the Inferior Constrictor Predicts Persistent Dysphagia with Definitive ChemorIMRT in Locally-Advanced Head and Neck Cancer, American Society for Radiation Oncology 54th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2012.
17. **Spratt DE**, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ: Metformin Improves Prostate Cancer-Specific Survival and Inhibits the Development of Castrate Resistant Metastasis, American Society for Radiation Oncology 54th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2012.
18. **Spratt DE**, Scala M, Cohen GN, Happersett L, Zelefsky MJ, Kollmeier M, Cox B, Yamada Y: A dosimetric analysis of prostate cancer treatment: Can SBRT really achieve what HDR brachytherapy can?, World Congress of Brachytherapy/ESTRO, Barcelona, Spain, Brachytherapy, 2012.
19. **Spratt DE**, Folkert M, Chan TA, Beal K, Yamada, Y: A Validation Study of the Temporal Relation of PostOperative Radiotherapy with Temozolomide for Glioblastoma Multiforme: Is the RTOG RPA Enough?, American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
20. **Spratt DE**, Kollmeier, MA, Zumsteg Z, Pei, X, Yamada, J, Polkinghorn W, Zelefsky MJ: Comparison of High Dose IMRT (86.4 Gy) to Combined Brachytherapy Plus IMRT for Intermediate Risk Prostate Cancer, American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
21. **Spratt DE**, Gordon Spratt EA, Shen W, Lacouture ME, Barker CA: Palliative Local Therapy for Skin Metastases: A Meta-Analysis, American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
22. **Spratt DE**, Zumsteg Z, Pei, X, Kollmeier, MA, Yamada, J, Polkinghorn W, Zelefsky MJ: Predictors of Castration Resistant Prostate Cancer after Definitive Radiotherapy: Impact of Failing Neoadjuvant Androgen Deprivation Therapy, American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
23. Romesser P, **Spratt DE**, Zumsteg Z, Kollmeier, MA, Pei, X, Yamada, J, Polkinghorn W, Zelefsky MJ: Prostate-Specific Antigen (PSA) Doubling Time at Time of PSA Relapse Is an Independent Predictor for Distant Metastasis and Survival after External Beam Radiation Therapy, American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
24. Zumsteg Z, **Spratt DE**, Romesser P, Kollmeier, MA, Pei, X, Yamada, J, Polkinghorn W, Zelefsky MJ: The Natural History and Patterns of Failure Following Biochemical Relapse in Prostate Cancer (PC) Patients Treated with Dose Escalated External Beam Radiotherapy (EBRT), American Society for Radiation Oncology 55th Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 2013.
25. Yang TJ, Pei X, Zhang Z, Kollmeier M, **Spratt DE**, Zumsteg ZS, Polkinghorn W, McBride S, Zelefsky MJ: Evaluation of PSA Patterns in Patients with Localized Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy, American Society for Radiation Oncology 56th Annual Meeting, San Francisco, CA, Int J Radiat Oncol Biol Phys, 2014.
26. **Spratt DE**, Fareedy S, Lindgren S, Robinson B, Larson SM, Lewis J, Bander NH, Scherr DS, Osborne JR: Molecular Imaging for Localized Prostate Cancer: Analysis of Two Prospective Phase 0 Trials of PSMA Targeted Immuno-PET and -SPECT, and Implications for the Radiation Oncologist, American Society for Radiation Oncology 56th Annual Meeting, San Francisco, CA, Int J Radiat Oncol Biol Phys, 2014.
27. Romesser PB, Pei X, **Spratt DE**, Zumsteg Z, Kollmeier MA, Polkinghorn W, Zelefsky MJ: Prostate Specific Antigen Bounce After Dose-Escalated Radiation Therapy For Prostate Cancer Is an Independent Predictor for Distant Metastasis and Overall Survival, American Society for Radiation Oncology 56th Annual Meeting, San Francisco, CA, Int J Radiat Oncol Biol Phys, 2014.
28. **Spratt DE**, Zelefsky MJ, Fareedy SB, Lindgren S, Osborne JR: Utility of FDG-PET in Clinical Neuroendocrine Prostate Cancer, American Society for Radiation Oncology 56th Annual Meeting, San Francisco, CA, Int J Radiat Oncol Biol Phys, 2014.
29. Evans M, Ulmert D, Holland J, Doran M, **Spratt DE**, Sawyers C, Lewis J: Imaging Androgen Receptor Signaling in Prostate Cancer with PET, Society of Nuclear Medicine, Journal of Nuclear Medicine, 2015.

30. Lockney NA, Siu CT, **Spratt DE**, Morrow M, Ng A, Powell SN, McCormick B, Cahlon O, Ho AY: A Pattern of Care Analysis of Nodal Irradiation in the Post Z0011 Era: Results of a Large Prospective Study, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 2015.
31. Escorcía FE, **Spratt DE**, Folkert MR, Zumsteg Z, Chan TA, Omuro AM, Gutin PH, Yamada Y, Beal K: Patterns of Salvage Treatment for High Grade Glioma in Patients Who Received Upfront Temozolomide, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 2015.
32. Laughney A, Murnane J, Genovese G, Elizalde S, Compton D, Kabeche L, **Spratt DE**, Zaki B, Bakhoun S: Targeting the Process of Mitotic Chromosome Segregation as a Novel Sensitizing Target to Radiation Treatment, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 2015.
33. Leeman JE, Alvarez JA, Osborne JR, Folkert MR, Alektiar KM, Karimi S, Lyo JK, Bilsky M, Laufer I, Yamada Y, **Spratt DE**: Early Magnetic Resonance Imaging Biomarkers to Predict Local Control After Stereotactic Body Radiation Therapy for Sarcoma Spine Metastases , ASTRO's 57th Annual Meeting, Int J Radiat Oncol Biol Phys, 2015.
34. Leeman JE, Bilsky M, Laufer I, Folkert MR, Taunk NK, Osborne JR, Zatzky J, Alektiar K, Yamada Y, **Spratt DE**: Detailed Spinal Axis Patterns of Failure Following SBRT for Metastatic Spinal Sarcoma, ASTRO's 57th Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 2015.
35. Doran M, **Spratt DE**, Wongvipat J, Ulmert D, Carver B, Sawyers C, Evans M: The tyrosine kinase inhibitor Cabozantinib resolves bone scans in mice with tibial fractures, Society of Nuclear Medicine, 2015.
36. Salami S, Udager A, Miller B, Palapattu G, Tomlins S, Chinnaiyan A, **Spratt DE**, Feng F, Kunju L, Wu A, Morgan T, Weizer A, Montgomery J, Lee C, Mehra R: Characterization of urothelial carcinoma with seminal vesicle involvement in locally advanced bladder cancer, ASCO Annual Meeting Proceedings, Chicago, 34, 2_suppl, 440, 2016.
37. Zhao SG, Chang SL, **Spratt DE**, Erho NG, Yu M, Ashab HADM, Yousefi K, Alshalafa M, Speers C, Tomlins SA, Den RB, Dicker AP, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Davicioni E, Nguyen PL, and Feng FY: A 24-Gene Predictor of Response to Postoperative Radiation Therapy in Prostate Cancer, ASTRO Annual Meeting, Boston, MA, Int J Radiat Oncol Biol Phys, 96, 2, S104, 2016.
38. Zumsteg Z, Beadle B, **Spratt DE**, Rivera A, Skinner H, Osborne J, Garden A, Lee N: The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study, ASTRO Head and Neck, Int J Radiat Oncol Biol Physics, 94, 4, 877, 2016.
39. Zhao SG, Chang SL, **Spratt DE**, Erho NG, Yu M, Ashab HA, Yousefi K, Alshalafa M, Speers C, Tomlins SA, Den RB, Dicker AP, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Davicioni E, Nguyen PL, Feng FY: A 24-Gene Predictor of Response to Postoperative Radiation Therapy in Prostate Cancer, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
40. Jackson WC, Desai NB, Tumati V, Lee JY, Dess RT, Soni PD, Abugharib A, Hamstra DA, Hearn JW, Sandler HM, Zumsteg ZS, Montgomery J, Hollenbeck B, Palapattu G, Tomlins SA, Mera R, Morgan T, Feng FY, **Spratt DE**: Anatomic Patterns of Recurrence Following Biochemical Relapse After Postprostatectomy Radiation Therapy: A Multi-institutional Study, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
41. Alluri PG, Kim C, Schipper M, Sun Y, **Spratt DE**, Cao Y, Heth J, Mammoser A, Junck L, Tsien CI, Lawrence TS, Hayman JA, Kim MM: Extent of Resection Influences Survival Outcomes Among Patients With a Single Resected Brain Metastasis Treated With Postoperative Fractionated Stereotactic Radiation Therapy, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
42. **Spratt DE**, Zhao SG, Chang SL, Cooperberg MR, Erho NG, Speers C, Mera R, Niknafs YS, Nguyen PL, Den RB, Dicker AP, Klein EA, Karnes RJ, Schaeffer EM, Davicioni E, Carroll P, Chinnaiyan A, Tomlins SA, Ross AE, Feng FY: Identification and Validation of Intrinsic Subtypes of Prostate Cancer, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
43. Soni PD, Moraes FY, Jackson WC, Gadia R, Dess RT, Lee JY, Palapattu G, Tomlins SA, Mera R, Morgan T, Hearn JW, Sandler HM, Hamstra DA, Leite ET, Zumsteg ZS, Feng FY, **Spratt DE**: Multicenter Independent Validation of the Zumsteg-Spratt Risk Classification System of Intermediate- and High-Risk Men Treated With Dose-Escalated Radiation Therapy Without Androgen Deprivation Therapy, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
44. Tumati V, **Spratt DE**, Jackson WC, Feng FY, Roehrborn C, Lotan Y, Pistenmaa DA, Laine AM, Folkert MR, Hannan R, Desai NB: Natural History of Progression After Biochemical Failure Following Postoperative Radiation Therapy in Prostate Cancer, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
45. **Spratt DE**, Vargas HA, Zumsteg ZS, Pernicka JG, Osborne J, McBride SM, Kollmeier MA, Pei X, Zelefsky MJ: Patterns of Lymph Node Failure After Dose-Escalated Radiation Therapy in Patients Who Did Not

Undergo Pelvic Lymph Node Irradiation: Implications for Extended Pelvic Lymph Node Coverage, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.

46. Dess RT, Jackson WC, Suy S, Lee JY, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, **Spratt DE**: Predictors of Multidomain Decline in Health-Related Quality of Life After Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
47. Jackson WC, Desai NB, Tumati V, Lee JY, Dess RT, Soni PD, Abugharib A, Hamstra DA, Hearn JW, Sandler HM, Zumsteg ZS, Montgomery J, Hollenbeck B, Miller D, Palapattu G, Tomlins SA, Mera R, Morgan T, Feng FY, **Spratt DE**: Predictors of Rapid Treatment Failure After Postoperative Radiation Therapy: A Multicenter Study, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
48. Dess RT, Jackson WC, Hamstra DA, Suy S, Lee JY, Zumsteg ZS, Sandler HM, Feng FY, Collins SP, **Spratt DE**: Prospective Patient-Reported Outcomes After Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer: Longitudinal Predictors of Potency Preservation, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
49. **Spratt DE**, Osborne J, Zumsteg ZS, Rebiez K, Leeman JE, Rivera A, Zelefsky MJ: Radium-223 Outcomes After Multiple Lines of Metastatic Castration-Resistant Prostate Cancer Therapy in Clinical Practice: Implication of Pretreatment Spinal Epidural Disease, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Phys, 2016.
50. Zumsteg ZS, **Spratt DE**, Pei X, Zhang Z, Woo K, Kollmeier M, McBride S, Sandler HM, Zelefsky MJ: Redefining Unfavorable Risk Prostate Cancer: A Novel Risk Stratification Paradigm for Enhanced Outcome Prediction Via Harmonization and Unification of Risk Stratification Criteria, ASTRO's 58th Annual Meeting, Boston, Int J Radiat Oncol Biol Physics, 2016.
51. **Spratt DE**, Cole A, Mehra R, Jackson W, Zhao S, Lee J, Tomlins S, Weizer A, Wu A, Montgomery J, Kunju L, Miller D, Hollenbeck B, Palapattu G, Feng F, Morgan T: Independent Surgical Validation of the 2015 Prostate Cancer Grade Grouping System, AUA, San Diego, J Urol, 195, 4, e1040-e1041, 2016.
52. **Spratt DE**, Chen Y, Mahal B, Osborne J, Zhao S, Morgan T, Palapattu G, Feng F, Nguyen P: Individual Patient Data Analysis In Randomized Clinical Trials: Impact of Race on Prostate Cancer Outcomes, AUA, San Diego, J Urol, 195, 4, e499, 2016.
53. Salami SS, Udager A, Miller BG, Palapattu GS, Tomlins S, Chinnaiyan AM, **Spratt DE**, Feng FY, Kunju LP, Wu AJ, Morgan TM, Weizer AZ, Montgomery JS, Lee CT, Mehra R: Characterization of urothelial carcinoma with seminal vesicle involvement in locally advanced bladder cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 34, 2S, 2016.
54. Loeb S, Ross AE, Santiago-Jiménez M, Haddad Z, Wang Q, Lam LL, Yousefi K, Davicioni E, Feng FY, Klein EA, Den RB, **Spratt DE**: Decipher correlation patterns on biopsy: Initial experience from 1,558 prospective patients, Prostate Cancer Foundation's 23rd Annual Scientific Retreat, San Diego, 2016.
55. **Spratt DE**, Yousefi K, Deheshi S, Ross AE...Klein EA, Karnes JR, Feng FY: Individual Patient Level Metaanalysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic Disease, Prostate Cancer Foundation's 23rd Annual Scientific Retreat, San Diego, 2016.
56. Skala S, Liu T, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J...**Spratt DE**, Jiang H, Mehra R.: Programmed Death Ligand 1 (PDL1) Expression in Upper Tract Urothelial Carcinoma, 2017 United States & Canadian Academy of Pathology Annual Meeting, San Antonio, 2017.
57. Speers C, Chandler B, Zhao SG, Liu M...**Spratt DE**, Wahl D, Hayes D, Feng FY, Pierce LJ.: Androgen Receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC), AACR Annual Meeting, Washington, D.C., 2017.
58. Soni PD, Abugharib A, Allen SG, Khan IA, Soliman M, Simons RE, Dess RT, **Spratt DE**: Adjustments for confounding variables in observational population-based studies in oncology and comparison to results from randomized controlled trials, ASCO Annual Meeting, Chicago, IL, 2017.
59. **Spratt DE**, Zhang J, Santiago-Jimenez M, Davis JW, Robert Den RB, Dicker A, Kane CJ, Pollack A, Ross A, du Plessis M, Choerung V, Yousefi K, Haddad Z, Davicioni E, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL: Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 35, 2017.
60. Speers CW, Chandler B, Zhao S, Liu M, Wilder-Romans K, Olsen E, Nyati S, Rae JM, Hayes DF, **Spratt DE**, Wahl DW, Feng FY, Pierce LJ.: Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (SEVI), a selective CYP17 lyase and AR inhibitor., ASCO annual meeting, Chicago, IL, 2017.

61. Sandler KA, Ciezki JP, Ross AE, Cook RR, Shaikh T, Stock RG, Merrick GS, Demanes DJ, Alam R, **Spratt DE**, Abu-Isa E, Wedde TB, Lilleby WA, Krauss DJ, Song DY, Reddy CA, Nickols NG, Steinberg ML, Horwitz EM, King CR, Kishan AU: Clinical outcomes for patients with Gleason Score 10 prostate adenocarcinoma: results a multi-institutional consortium study, ASTRO 58th Annual Meeting, San Diego, Int J Radiat Oncol Biol Phys, 2017.
62. Kishan AU, Ciezki JP, Ross AE, Cook RR, Shaikh T, Stock RG, Merrick GS, Demanes DJ, Alam R, **Spratt DE**, Abu-Isa E, Wedde TB, Lilleby WA, Sandler KA, Song DY, Reddy CA, Nickols NG, Steinberg ML, Horwitz EM, King CR: Extremely Dose Escalated Radiotherapy Improves Cancer-Specific Survival Compared with Radical Prostatectomy or Conventionally Dose-Escalated Radiotherapy in Gleason Score 9-10 Prostate Adenocarcinoma: A Multi-institutional Analysis of 1403 Patients, ASTRO 58th Annual Meeting, San Diego, Int J Radiat Oncol Biol Phys, 2017.
63. Sandler KA, Ciezki JP, Ross AE, Cook RR, Shaikh T, Stock RG, Merrick GS, Demanes DJ, Alam R, **Spratt DE**, Abu-Isa E, Wedde TB, Lilleby WA, Krauss DJ, Song DY, Reddy CA, Nickols NG, Steinberg ML, Horwitz EM, King CR, Kishan AU: Whole pelvis radiation therapy does not significantly improve prostate-cancer specific survival in patients with Gleason Score 9-10 prostate adenocarcinoma: An analysis of 942 patients treated in the modern era, ASTRO 58th Annual Meeting, San Diego, Int J Radiat Oncol Biol Phys, 2017.
64. Dess RT, Hartman HE, Soni PD, Jackson WC, Suy S, Abugharib A, Mehra R, Schipper M, Feng FY, Hamstra DA, Collins SP, and **Spratt DE**: Erectile Function After Stereotactic Body Radiation Therapy for Prostate Cancer: A Validated Model-Based Comparison to Nerve-Sparing Prostatectomy, Conventional Radiation Therapy, and Brachytherapy, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, E228, 2017.
65. Dess RT, Abugharib A, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, and **Spratt DE**: External Beam Radiation Therapy With or Without Low Dose Rate Brachytherapy: Analysis of Favorable and Unfavorable Intermediate-Risk Prostate Cancer Patients, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, E227, 2017.
66. Younge KC, Marsh R, Owen D, Geng H, Xiao Y, **Spratt DE**, Foy J, Wu QRJ, Yin FF, Ryu S, and Matuszak MM: Improving Quality and Consistency in Clinical Trials via Knowledge-Based Planning, NRG Oncology RTOG 0631, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, s107, 2017.
67. Jackson DC, Suresh K, Abugharib A, Tumati V, Dess RT, Soni PD, Zhao SG, Hollenbeck B, George A, Kaffenberger S, Miller DC, Hearn JWD, Tomlins S, Feng FY, Mehra R, Palapattu G, Schipper M, Morgan TM, Desai NB, and **Spratt DE**: Intermediate Endpoints After Postprostatectomy Radiation Therapy: 5Year Distant Metastases to Predict Overall Survival, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, E242, 2017.
68. Boreta L, Xu M, Wu SY, Wu A, Nguyen H, Chang A, Roach III M, **Spratt DE**, Feng FY, Carroll P, Hope TA: Location of Recurrence by Gallium-68 PSMA PET Scan in Prostate Cancer Patients Eligible for Salvage Radiation Therapy, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, s98, 2017.
69. Hwang W, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, **Spratt DE**, Hearn JWD, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw S, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, and Efstathiou JA: Multi-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, S96, 2017.
70. Zhao SG, Lehrer J, Chang SWL, Erho NG, Sjostrom M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Das R, Chang AJ, Nguyen PL, Davicioni E, Ross AE, Fong L, **Spratt DE**, and Feng FY: Novel Associations Between the Immune Landscape of Prostate Cancer and Postoperative Radiation Response, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, S2, 2017.
71. Dess RT, Devasia TP, Jackson WC, Soni PD, Suy S, Feng FY, Schipper M, Collins SP, and **Spratt DE**: Prostate Stereotactic Body Radiation Therapy: An Assessment of Modern Sexual Aid Utilization and Efficacy Following Definitive Treatment for Localized Prostate Cancer, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, S39, 2017.
72. Jackson WC, Tsien C, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, **Spratt DE**, Cao Y, Lawrence TS, and Kim MM: Standard Dose and Dose-Escalated Radiation Therapy Are Associated with Favorable Survival in Select Elderly Patients with Newly Diagnosed Glioblastoma, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, E81, 2017.
73. Hitchcock W, Younge KC, Gemmete J, Chaudhary N, Smith S, Archer PG, Matuszak MM, Park P, Szerlip NJ, and **Spratt DE**: Superiority of CT Myelography over MRI in Delineating the Spinal Cord during Spine Stereotactic Radiosurgery, ASTRO Annual Meeting, San Diego, CA, Int J Radiat Oncol Biol Phys, 99, 2, e79, 2017.

74. **Spratt DE**, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM...Freedland SJ, Klein EA, Karnes JR, Feng FY: Individual Patient Level Meta-analysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic Disease, Genitourinary Cancers Symposium, Orlando, 2017.
75. Feng FY, Zhao S, Chang LS, Erho N, Lehrer J...Klein E, Davicioni E, Ross A, Schaeffer EM, Nguyen PL, Carroll P, Karnes J, **Spratt DE**: Luminal and basal subtyping of prostate cancer, Genitourinary Cancers Symposium, Orlando, 2017.
76. Agrawal S, Efstathiou J, Michalski J, Pisansky TM, Koontz B, Zietman A, Lee RW, Stephans KL, **Spratt DE**, Hearn J, Gao T, Kattan M, Stephenson AJ, Tendulkar RD: Prostate Cancer Specific Mortality and Overall Survival Outcomes for Salvage Radiation Therapy after Radical Prostatectomy, Genitourinary Cancers Symposium, Orlando, 2017.
77. Udager A, Hovelson D, McDaniel AS, Salami SS, **Spratt DE**, Palapattu GS, Weizer A, Hafez KS, Montgomery JS, Chinnaiyan AM, Alva A, Tomlins SA, Mehra R: Squamous cell carcinoma (SqCC) of the urinary bladder: a clinicopathologic and molecular study with PDL1 immunohistochemistry (IHC) correlation, United States & Canadian Academy of Pathology Annual Meeting, San Antonio, TX, 2017.
78. McBride SM, Zelefsky MJ, **Spratt DE**, Kollmeier M, Slovin SF, Aghalar J, Hearn JWD, Den RB, Deville C, Borofsky K, Xiao H, Abida W, Scher HI, Rathkopf DE: Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa), ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 36, Suppl, 2018.
79. **Spratt, DE**: Precision Risk Stratification and Treatment in Biochemical-Recurrent Prostate Cancer, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 37, 2018.
80. Jackson WC, Dess RT, Soni PD, McLaughlin PW, **Spratt DE**: A Meta-Analysis of Randomized Trials to Compare the Added Benefit of a Brachytherapy Boost Versus the Addition of Androgen Deprivation Therapy to External Beam Radiation Therapy in Men with Intermediate and High Risk Prostate Cancer, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S148, 2018.
81. Laucis AM, Sun Y, Schipper M, Maurino C, Saripalli A, McFarlane M, Arenberg D, Ten Haken RK, Kong FM, Matuszak MM, **Spratt DE**, Pierce LJ, Hayman JA, Paximadis PA, and Jolly S: Active Smoking Is Not Associated with Increased Radiation-Induced Toxicity in Locally Advanced Lung Cancer Patients, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S231, 2018.
82. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio III PF, Mouw K, King M, Choueiri TK, Trinh QD, Hoffman KE, **Spratt DE**, Feng FY, Nguyen PL: Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S145, 2018.
83. **Spratt DE**, Dess RT, Hartman HE, Mahal BA, Jackson WC, Soni PD, Alshalalfa M, Fishbane N, Zumsteg ZS, Shipley WU, Pisansky TM, Roach III M, Zhao SG, Speers C, Davicioni E, Schipper M, Nguyen P., Schaeffer EM, Feng FY, Sandler HM: Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S3, 2018.
84. Foster B, Jackson WC, Foster CC, Dess RT, Abu-Isa EI, McLaughlin PW, Merrick GS, Hearn JWD, **Spratt DE**, Liauw S, Hamstra DA: Application of a Prognostic Stratification System for High-Risk Prostate Cancer to Patients Treated with Radiation Therapy: Implications for Treatment Optimization, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e109, 2018.
85. Hall WA, Liu S, Fishbane N, Xu M., Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll P, Nguyen PL, Lawton CAF, **Spratt DE**, Feng FY: Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S98, 2018.
86. Zhao S., Decker P, **Spratt DE**, Chang SWL, Feng FY, Kim MM, Speers C, Eckel-Passow J, Carlson B, Tuma AC, Lawrence TS, Yu M, Sarkaria JN, Wahl DR: Development and Validation of Xenograft-Based Platform-Independent Gene Signatures That Predict Response to Alkylating Chemotherapy, Radiation, and Combination Therapy in Glioblastoma, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, s47, 2018.
87. Xu MJ, Kornberg Z, Gadzinski A, Diao D, Cowan J, Wu SY, Boreta L, **Spratt DE**, Nguyen H, Roach III M, Hope T, Carroll P, and Feng FY: Employing Molecular Imaging to Understand Tumor Genetic Risk Scores: PSMA Nodal Involvement Associated with High-Risk Decipher in Prostate Cancer, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S163, 2018.
88. Gharzai LA, Green M, Griffith K, Else T, **Spratt DE**, Miller B, Worden F, Hammer GD, Giordano T, Hesseltine E, Sabolch A, Ben-Josef E, Jolly S: Improvement in Recurrence-free Survival with Adjuvant

Radiation in Adrenocortical Carcinoma, ASTRO Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e90, 2018.

89. Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck B, George A, Kaffenberger S, Salami S, Hearn JWD, Jolly S, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, and **Spratt DE**: Prostate Cancer-Specific Mortality Following Salvage Post-Prostatectomy Radiation Therapy: A Competition Between Age and Time to Biochemical Failure, ASTRO's Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e120, 2018.
90. Wang C, Raldow A, King CR, Kupelian PA, Nickols N, Chang AJ, Steinberg ML, **Spratt DE**, Nguyen PL, and Kishan AU: Racial Disparity in Androgen Deprivation Therapy Utilization for Men with High-Risk Prostate Cancer Treated with Intensity-Modulated Radiation Therapy in the Modern Era – A SEERMedicare Linked Database Analysis, ASTRO's Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e147, 2018.
91. Beeler WH, Jackson WC, Gharzai LA, Jairath NK, Nycz D, Broderick M, Kim MM, Owen D, Gemmete J, Chaudhary N, Smith S, Park P, Archer PG, Szerlip NJ, **Spratt DE**, and Younge KC: Safety, Efficacy, and Setup Accuracy of Patients Undergoing Multi-Level Spine Stereotactic Radiosurgery, ASTRO's Annual Meeting, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e230, 2018.
92. Muralidhar V, **Spratt DE**, Feng FY, Davicioni E, Yousefi K, Zhang J, Wang Q, Choerung V, Nguyen PL: Genomic Validation of Three-Tiered Sub-Classification of High-Risk Prostate Cancer., ASTRO's, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, s99, 2018.
93. Jolly S, Mancini Jr. BR, Hayman JA, Boike TP, Griffith K, Moran JM, Dominello MM, Fireman M, Pierce LJ, **Spratt DE**: Heterogeneity in the Treatment of Bone Metastases: A Contemporary Statewide Practice Pattern Analysis., ASTRO's, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e443, 2018.
94. McFarlane M, Sun Y, Schipper M, Maurino C, Laucis AM, Saripalli A, Ten Haken RK, Kong FM, Matuszak MM, **Spratt DE**, Pierce LJ, Hayman JA, Paximadis PA, and Jolly S: Impact of Comorbidities on Acute Toxicity in Patients Receiving Radiation Therapy for Locally Advanced Lung Cancer, ASTRO's, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e694, 2018.
95. Kim MM, Parmar H, Aryal MP, Schipper M, Devasia TP, Kesari S, Morikawa A, **Spratt DE**, Junck L, Hayman JA, Lawrence TS, Tsien C, Aiken R, Goyal S, Knox SJ, Caroen S, Carter C, Oronsky B, Cao Y, and Lao C: Initial Clinical and Advanced Imaging Outcomes from a Multi-Institutional Phase I DoseEscalation Trial of RRx-001 Plus Whole Brain Radiation for Patients with Brain Metastases, ASTRO's, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, e266, 2018.
96. Berlin A, Moraes FY, Koven A, Salgado NS, Jiang H, Glicksman R, Leite ETT, Silva JLF, Gadia R, Fleshner NE, Chung P, Catton CN, Zumsteg ZS, Morgan TM, Hearn JWD, Mehra R, Dess RT, Feng FY, Finelli A, **Spratt DE**: International Multicenter Validation of an Intermediate-Risk Subclassification of Men Treated with Radical Treatment Without Hormone Therapy, ASTRO's, San Antonio, TX, Int J Radiat Oncol Biol Phys, 102, 3, S97, 2018.
97. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueire TK, Trinh QD, Hoffman KE, **Spratt DE**: Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
98. Mahal BA, Yang DD, Wang N, Alshalalfa M, Davicioni E, Choerung V, **Spratt DE**, Martin NE, Mouw KW, Orio PF, Choueire TK, Trinh QD, Feng FY, Nguyen PL: Clinical and genomic characterization of lowprostate-specific antigen, high-grade prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
99. Mahal BA, Yang DD, Wang N, Alshalalfa M, Davicioni E, Choerung V, **Spratt DE**, Martin NE, Mouw KW, Orio PF, Choueiri TK, Trinh QD, Feng FY, Nguyen PL: Clinical and genomic characterization of lowprostate-specific antigen, high-grade prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
100. Hovelson D, Salami SS, Kaplan JB, Mathieu R, Udager A, Curci N, Lee M, DeLaVega LL, Susani M, Rioux-Leclercq N, **Spratt DE**, Morgan TM, Davenport M, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS: Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
101. Kim W, Small EJ, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, Alumkal JJ, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, Thomas GV, Davicioni E, Ryan CJ, **Spratt DE**, Feng FY: Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
102. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, **Spratt DE**, Hearn JWD, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz M, Pollack A, Moghanaki D, Anscher M, Den

- RB, Zietman AL, Stephenson AJ, Efstathiou JA: Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
103. Nguyen PL, Zhang J, Yousefi K, Davicione E, Den RB, Feng FY, **Spratt DE**: Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
 104. **Spratt DE**, Alshalalfa M, Weiner A, Fishbane N, Mehra R, Walter R, Erho N, Dicker A, Freedland SJ, Karnes J, Glass A, Weinmann S, Davicion E, Ross A, Den RB, Feng FY, Schaeffer EM: Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 36, 6S, 2018.
 105. **Spratt DE**, Mehra R, Hearn J, Tomlins S, Hollenbeck B, George A, Kaffenberger S, Salami S, Morgan T, Chinnaiyan A, Palapattu G: Neoadjuvant SBRT prior to Prostatectomy for High Risk Prostate Cancer, Prostate Cancer SPORE Annual Retreat, Fort lauderdale, Florida, 2018.
 106. Reichert Z, Smith DC, Morgan TM, Piert M, Tomlins SA, FCackowski FC, Caram MV, Hearn JWD, Palmboos PL, Schonewolf C, Yentz SE, **Spratt DE**: Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial, ASCO ANNUAL MEETING, Chicago, IL, J Clin Oncol, 37, 2019.
 107. McBride SM, Zelefsky MJ, **Spratt DE**, Paller CJ, Lollmeier M, Slovin SF, Aghalar J, Hearn JWD, Den RB, Deville C, Xiao H, Abida W, Scher HI, Rathkopf DE: Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 37, Suppl, 2019.
 108. **Spratt, DE**: Therapeutic Advances, Balancing Quality of Life, ASCO Annual Meeting, Chicago, IL, 2019.
 109. Gharzai LA, Hayman JA, Mancini BR, Jr., Beeler WH, Pierce LJ, Moran JM, Dominello MM, Boike TP, Griffith K, Jolly S, **Spratt DE**: Practice Pattern Treatment Recommendations for the Treatment of Bone Metastases: A Statewide Survey, ASTRO Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E575, 2019.
 110. Wilkie JR, Hochstedler K, Schipper M, Matuszak MM, Paximadis P, Dominello MM, Grills IS, Hayman JA, Dess RT, Pierce LJ, **Spratt, DE**: Association between Adverse Events and Quality of Life in Patients Treated with Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S95-S96, 2019.
 111. Jolly S, Hochstedler K, Paximadis P, Hayman JA, Dominello MM, Burmeister JW, Grills IS, Dess RT, Dragovic AF, Movsas B, Ajlouni M, Frase7 C, Kestin LL, Wilson M, Bergsma DP, **Spratt DE**, Moran JM, Pierce LJ, Schipper M, Matuszak MM: Changing Practice Patterns in the Radiation Treatment Delivery for Locally Advanced Lung Cancer: Results from a Statewide Consortium, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E488, 2019.
 112. Levin-Epstein R, Cook K, Chu FI, Ciezki JP, Stock RG, Merrick GS, Demanes DJJ, **Spratt DE**, Abu-Isa EI, Pomerantz M, Tran PT, Nguyen PL, Wedde T, Lilleby W, Krauss DJ, Alam R, Steinberg ML, Horwitz EM, King CR, Kishan AU: Clinical Outcomes among Patients with Radiorecurrent Gleason Grade Group 5 Prostate Cancer: Impact of Initial Treatment Strategy, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E289, 2019.
 113. Beeler WH, Hartman HE, Allen SG, Gharzai LA, Jackson WC, Dess RT, Feng FY, Schipper M, Soni PD, and **Spratt DE**: Comparison of Population-Based Observational Studies to Randomized Controlled Trials in Prostate Cancer, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S182, 2019.
 114. Jaworski L, Dominello MM, Heimbürger DK, Mancini Jr. BR, Boike TP, Schipper M, Griffith K, Moran JM, Pierce LJ, Hayman JA, McLaughlin PW, Narayana V, Mislmani M, Paximadis PA, Jones N, Jolly S, Chuba PJ, Dess RT, **Spratt DE**: Contemporary Practice Patterns for Intact and Post-Operative Prostate Cancer: Results from a Statewide Collaborative, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E282, 2019.
 115. Moran JM, Dominello MM, Wilson M, Parker J, Bumeister JW, Gardner SJ, Fraser C, Miller L, Baldwin K, Mietzel M, Grubb M, Kendrick D, Pierce L, **Spratt DE**, Hayman JA: Contemporary Practice Patterns for Radiotherapy of Bone Metastases: Preliminary Analysis of Prospective Data from a Statewide Consortium Focusing on Extended Fractionation, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S153, 2019.
 116. Parikh NR, Chang EM, Nickols NG, Rettig M, Raldow A, King CR, Steinberg ML, Feng FY, **Spratt DE**, Tran PT, Kishan Au: Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent

- Hormone Sensitive Prostate Cancer, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S100, 2019.
117. Dess RT, Suresh K, Zelefsky MJ, Cooperberg MR, Mahal BA, Davis BJ, Horwitz EM, DeWeese TL, Song D, Berlin A, Moraes F, Briganti A, Gandaglia G, Freedland SJ, Feng FY, Carroll P, Karnes RJ, Kattan MW, Schipper M, **Spratt DE**: Development and Validation of the First AJCC Compliant Clinical Staging System for Localized Prostate Cancer: Results from a Multicenter International Study, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S40, 2019.
 118. Jackson WC, Kishan AU, Beeler WH, Soni PD, Hall WA, Mahal BA, Feng FY, Dess, RT, Zumsteg ZS, Zaorsky NG, Stish BJ, Efstathiou JA, Showalter TN, Pisansky TM, **Spratt DE**: External Beam Radiotherapy Plus Long-Term ADT Versus Combination Brachytherapy Plus Short-Term ADT for High Risk Prostate Cancer: A Network Meta-Analysis of Randomized Trials, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E281, 2019.
 119. Den RB, Marascio JA, **Spratt DE**, Zhang J, Trabulsi E, Bloom M, Le T, Davicioni E, Gore JL, Mann M, Mark JR, Calvaresi A, Hurwitz MD, Kelly WK, Lallas C, Knudsen KE, Gomella LG, Dicker AP: First Prospective Results Assessing the Clinical Utility and Clinical Benefit of Genomic Classifier Testing in Men Post-Prostatectomy, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E274, 2019.
 120. Campbell SR, Agrawal S, Tom MC, Efstathiou JA, Zietman AL, Michalski JM, Abramowitz MC, Pollack A, **Spratt DE**: Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, S38, 2019.
 121. Jackson WC, Silva J, Hartman H., Dess RT, Beeler WH, Jaworski L, Soni PD, Mahal BA, Kishan AU, Mehra R, Hearn JWD, Morgan TM, Kaffenberger S, Nguyen PL, Desai NB, Feng FY, Zumsteg ZS, **Spratt DE**: Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E280, 2019.
 122. Kishan AU, Romero T, Grogan T, Alshalalfa M, Boutros P, Rettig M, Reiter RE, Tran PT, Nguyen PL, Nickols NG, Davicioni E, **Spratt DE**, Feng FY, Den RB, Freedland SJ, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Weidhaas JB: Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E286, 2019.
 123. Cousins MM, Aghdam N, Dess RT, Suy S, Desai NB, **Spratt DE**, Collins SP, Jackson WC: Transient Declines in Serum Testosterone Levels Following Prostate SBRT Do Not Drive Post-treatment Declines in Health-Related Sexual Quality of Life, ASTRO's Annual Meeting, Chicago, IL, Int J Radiat Oncol Biol Phys, 105, 1, E272, 2019.
 124. Mahal AR, Butler S, Franco II, Pike LR, Zhao S, Sanford NN, Dess RT, Feng FY, D'Amico AV, **Spratt DE**, Yu JB, Nguyen PL, Rebbeck T, Virgil BA: Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 37, 2019.
 125. Kishan AU, Romero T, Elashoff D, Grogan T, Rettig M, Reiter RE, Tran PT, Nguyen PL, Nickols NG, Davicioni E, **Spratt DE**, Feng FY, Weidhaas JB: Genomic biomarkers to predict outcome in Gleason Score 9-10 disease, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 37, 2019.
 126. Muralidhar V, Zhang J, **Spratt DE**, Feng FY, Davicioni E, Yousefi K, Wang N, Choerung V, Nguyen PL: Genomic validation of three-tiered sub-classification of high-risk prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 37, 7s, 2019.
 127. Salami SS, Kaplan JB, Nallandhighal S, Takhar M, Tosoian JJ, Lee M, Yoon J, Hovelson DH, Plouffe KR, Kaffenberger SD, George AK, Montgomery JS, Davenport M, You S, Tomlins SA, Curci NE, Kim HL, **Spratt DE**, Udager AM, Palapattu GS: Radiogenomic characterization of multifocal prostate cancer, Genitourinary Cancers Symposium, San Francisco, CA, J Clin Oncol, 37, 7S, 2019.
 128. Kim MM, Parmar H, Aryal MP, Caroen S, Devasia T, Schipper MJ, Morikawa A, **Spratt DE**, Hayman J, Junck L, Lawrence TS: DCE-MRI Evaluation of 10 patients with brain metastases treated with RRx-001, a Myc inhibitor and a CD47 and PD-L1 downregulator, in a phase I/II trial called BRAINSTORM, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, e14509-e14509, 2020.
 129. Farha M, Jairath N, El Naqa I, **Spratt DE**, Lawrence T: MR1 in combination with tumor mutational burden and PD-1/PD-L1 expression as a potentially novel clinical predictor for T cell exhaustion and immune checkpoint inhibitor response, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 3109-3109, 2020.
 130. **Spratt DE**, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson W, Schipper MJ, Michalski JM, Lee R, Pisansky TM, Feng FY, Shipley WU, Sandler HM, Roach M, Sun C,

Lawton CA: Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials, ASCO Annual Meeting, Chicago, IL, J Clin Oncol, 5584-5584, 2020.